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ABSTRACT 
Bleeding from a peptic ulcer is a common and life threatening event. To reduce the 
risk for further bleeding, normal coagulation and a stable clot formation are pivotal 
factors. In vitro studies have shown that neither coagulation nor platelet aggregation 
can take place if pH is below 5.4. Efforts have therefore been made to improve 
intragastric hemostasis by administrating antacids or histamine-2-receptor 
antagonists to raise intragastric pH to or above this level. The effect of these 
treatments has, however, been limited. In vivo studies have shown that if omeprazole 
is given as a primed continuous infusion a stable intragastric pH above 5.4 can be 
reached. 
The aims of the present study were: 1) To determine the dose regimens for 
intravenous omeprazole infusion and subsequent per oral administration to stabilize 
intragastric pH at a levels alleged to allow hemostasis and facilitate further ulcer 
healing. 2) To study if th is omeprazole dose regimen improved the outcome for high 
risk patients with peptic ulcer bleeding (PUB). 3) To identify risk factors for fatal 
outcome in both short and long term perspective in patients with PUB. 
Healthy volunteers and duodenal ulcer patients in remission were included in the 
dose-finding study. An omeprazole infusion, 80 mg + 8 mg/h for 72 hours, followed 
by omeprazole 20 mg orally once daily fulfilled the requirements set up based upon 
intragastric pH measurements. This dose regimen was evaluated in two separate 
clinical studies enrolling patients with acute PUB. One study included patients 60 
years or over (n = 322), while the other study included patients in hemorrhagic shock 
(n = 265). Both studies showed consistently better outcomes in the groups treated 
with omeprazole when either assessed by a defined overall outcome score, blood 
transfusions requirements or need for surgical/endoscopic interventions. The 
cumulative mortality was approximately 1% after the first three days of admission 
but rose almost linearly during the subsequent three weeks reaching about 6% at day 
21. Most deaths were caused by cardiovascular events. 
In a multiple logistic regression analysis performed on a subset of the data, age, 
coronary heart disease, blood pressure on admission and absence of previous ulcer 
were significantly associated with mortality. 
Patients above 60 years admitted to hospital due to a PUB in Göteborg during 1989 to 
1993 (n=687) were found to have a 5.5% cumulative mortality at 30 days. Age and 
Forrest class significantly influenced mortality during this period. During the 
subsequent 5 year follow-up mortality was significantly higher in women compared 
to matched controls while no significant difference was found in men. 
Finally, 1020 patients with a PUB were selected from the General Practitioners 
Research Database in the UK. Day 30 mortality was 4.4% and again high age and 
absence of previous ulcer had a significant impact upon mortality. 
In conclusion, an omeprazole infusion 80 mg + 8 mg/h for 72 hours significantly 
improved clinical outcome in high risk patients with PUB. Mortality occurred almost 
linearly over the first month of admission and most patients died due to 
cardiovascular events. High age and absence of previous ulcer significantly increased 
the mortality risk. 
ISBN 91-628-2873-8 
This thesis is based upon the following studies which are referred to in the text by 
their Roman numerals: 
I Hasselgren G, Keelan M, Kirdeikis P, Lee J, Röhss K, Sinclair P, 
Thomson ABR. To optimize acid suppression for patients with 
peptic ulcer bleeding — an intragastric pH-metry study with 
omeprazole. Accepted for publication in Eur ] Gastroenterol 
Hepatol 
II Hasselgren G, Lind T, Lundeli L, Aadland E, Efskind P, Falk A, 
Hyltander A, Söderlund C, Eriksson S, Fernström P. Continuous 
intravenous infusion of o meprazole in elderly patients with peptic 
ulcer bleeding. Scand J Gastroenterol 1997;32:328-333. 
III Schaffalitzky de Muckadell OB, Havelund T, Harling H, Boesby S, 
Snel P, Vreeburg EM, Eriksson S, Fernström P, Hasselgren G. Effect 
of omeprazole on the outcome of endoscopically treated bleeding 
peptic ulcers. Scand J Gastroenterol 1997;32:320-327. 
IV Hasselgren G, Blomqvist A, Eriksson S, Henningsson A, Lundeli L. 
The short and long term course of elderly patients with peptic ulcer 
bleeding — Analysis of factors influencing fatal outcome. Accepted 
for publication in Eur J Surg. 
V Hasselgren G, Carlsson J, Lind T, Schaffalitzky de Muckadell O, 
Lundeli L. Risk factors for rebleeding and fatal outcome in elderly 
patients with acute peptic ulcer bleeding. Accepted for publication 
in Eur J Gastroenterol Hepatol 
VI Garcia Rodriguez LA, Ruigömez A, Hasselgren G, Wallander M-A, 
Johansson S. Comparison of mortality from peptic ulcer bleed 
between patients with or without peptic antecedents. Accepted for 
publication in Epidemiology. 
TABLE OF CONTENTS 
Abbreviations 8 
Historical aspects 9 
Background 12 
Epidemiology of peptic ulcer bleeding 12 
Mortality in peptic ulcer disease 12 
Current treatment options 14 
Acid suppressing agents 15 
Antifibrinolytic drugs 18 
Endoscopic treatment 20 
Surgery 22 
Risk factors 23 
Aim of the present study 26 
Patients and Methods 27 
Study I 27 
Studies II, and III 29 
Study IV 32 
Study V 34 
Study VI 36 
Risk factor analysis (IV, V, VI) 39 
Variable selection 39 
Statistical models 40 
Results and Comments 44 
Control of intragastric pH (Study I) 44 
Omeprazole infusion in pe ptic ulcer bleeding (Study II and III) 48 
Effects of omeprazole upon hemostatic mechanisms (unpubl. data) 58 
Risk factor analyses (Study IV, V, VI) 62 
Summary and clinical considerations 72 
Acknowledgments 75 
References 77 

ABBREVIATIONS 
ASA Acetylsalicylic acid 
ASGE American Society for Gastrointestinal Endoscopy 
AUC Area under the plasma concentration curve 
B.i.d. Twice daily 
CI Confidence interval 
OR Odds ratio 
GP General practitioner 
GPRD General Practice Research Database 
H2RA Histamine-2-receptor antagonist 
NSAID Non steroidal anti-inflammatory drugs 
O.d. Once daily 
OTC Over the counter 
PU Peptic ulcer 
PUB Peptic ulcer bleeding 
RR Relative risk 
UGIB Upper gastrointestinal bleeding 
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HISTORICAL ASPECTS 
On April 15"', 1830 a 29 years old Parisian carpenter experienced a burning epigastric 
pain. The pain increased in intensity and on the 30"' he began to vomit red blood and 
was admitted to a hospital in Paris. He was found to be in shock with vague pulse and 
severe anemia. The next day he had recovered somewhat, but on May the 2nd he had a 
further massive hematemesis and abruptly died. When the autopsy irns performed a 
large peptic ulcer was found with a solitary artery extruding from its base. 
This patient history was described in "Anatomie pathologique du corps 
human" 1829 - 35 by Jean Cruveilhier (1791-1874) who was professor of 
anatomy in Paris and the first person to fully describe the peptic ulcer, its 
complications and treatment (37). Up until this time ulcers had been looked 
upon as merely a curious autopsy finding. The production of hydrochloric 
acid in the stomach had been described by Prout a few years before (1823), 
which had led to Abercrombie's recommendation of a diet of milk and flour 
products . Shortly thereafter antacids i.e., soda and chalk were recommended 
as an effective therapy (26). 
It was, however, Cruveilhier who brought these different recommendations 
together and outlined a detailed diet therapy, he also emphasized the need for 
prolonged treatment. 
During the subsequent years the diet therapy became more and more specific 
and the need for strict confinement to bed for several weeks was seriously 
recommended. Boas (15) gave detailed instructions on how to treat a patient 
with a peptic ulcer bleeding (PUB) and besides rest and complete fasting he 
suggested "injection of a full syringe of erg ot in the stomach region" instead 
of the traditional medication with lead acetate, iron chloride or turpentine oil. 
In those patients who required nutrients, a specific recipe for an enema with 
milk, egg yolk, salt flour and red wine was given. In certain cases, warm port 
wine was added to the enema to further improve the efficacy. If the patient 
needed something to improve his general health status, 2 mg arsenic up to ten 
10 Historical aspects 
times daily was recommended. This therapy was continued for several weeks 
after the bleeding. 
The fundamentals of this therapy with starvation for several days before oral 
nutrients were resumed remained until the introduction of the "Sippy 
regime" in 1915,(144). Sippy suggested frequent feeding and administration of 
alkalids, "Sippy powder", and gastric aspiration at night. Some years later the 
radical recommendations by Meulengracht was presented (235). He presented 
a study on 251 patients who were given a combination of pureed diet, 
antacids, sedation and iron replacement starting already the day after 
admission and claimed a drastic reduction of mortality, to only 1.5%, in 
contrast to the 7.9% which was reported from a neighboring hospital in 
Copenhagen. 
The same year Marriot and Kekwick ( l  1 0 )  reported on a method where blood 
was continuously infused by a drop. Blood tr ansfusions had been used early 
this century when blood grouping was first established by Landsteiner in 
1901 but until 1935 these entailed direct intravenous only which limited the 
usefulness. 
The combination of antaci ds, sedation and commencing a specific diet within 
24 hours together with blood transfusions constituted the fundamentals of 
medical ulcer bleeding treatment until the introduction of more potent acid 
inhibition agents in the middle of 1970's. 
Gastroduodenal surgery in the treatment of pe ptic ulcers was first described 
in the 1880's when various procedures were presented by Billroth, Heinecke 
and Rydygier (83). Mikulicz (116) was the first to describe an operation for a 
bleeding peptic ulcer in 1888 opening the pylorus and cauterizing a bleeding 
posterior duodenal ulcer. Vagotomy, combined with pyloroplasty in the 
treatment of  ble eding ulc ers  wa s not  desc ribed unti l  1952 by Dorton ( 4 1 )  
despite the fact that Latarjet described the vagal effects upon the acid 
secretion already in 1922 (102) .  
Surgery for bleeding peptic ulcers was for long considered as a very risky 
procedure until Gordon Gordon-Taylor (being both surgeon and rear-
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admiral), pointed out in a v ery readable article in 1946 (53) that much of this 
disrepute came from the fact that surgery was often seen as a last, desperate 
measure to save a patients life. He reported that if h e could operate shortly 
after hospital admission he could reduce mortality from 36% to 5.5% and 
that patients could "be rescued from the jaws of death by courageous 
surgery" if the operation was performed at the right time. The surgical 
procedures varied from simple hemostasis and oversewing to extensive 
resections. It is interesting to note that the importance of e arly surgery was 
confirmed many years later by several authors (83 ,119) .  
Gastric cooling was introduced by Wangensteen in 1958 (160)  with the aim to 
reduce peptic activity, secretion of acid, gastric blood flow and gastric 
motility. The cooling was accomplished by intragastric balloons, cooling 
machines or ice water installation. Despite the findings by McFarland in 1968 
(111) indicating that gastric cooling had no advantage in comparison with 
conservative treatment, the procedure has kept its popularity until today. 
A significant step forward in the clinical management of ulcers was taken 
with the introduction of fiberoptic instruments in the early 1960's (71)  
allowing the precise identification of the bleeding source. The technique for 
endoscopic hemostasis was first described in the middle of the 1970's, 
however, it took almost 20 years until the use of the rapeutic endoscopy came 
into routine clinical p ractice. The first results from randomized clinical trials 
using laser to photocoagulate the ulcer were published in 1981 (77 ,  149) .  
Results of electrocoagulation (227) and injection techniques (31) were 
presented later. The results of therapeutic hemostasis through the endoscope 
in the treatment of PUB has been described in many studies (34, 151) and 
constitutes the cornerstone for the treatment of b leeding ulcers today. As a 
consequence, the need for surgery has again been limited to those patients in 
whom the bleeding cannot be controlled by other methods. 
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BACKGROUND 
Epidemiology of peptic ulcer bleeding 
Acute upper gastrointestinal bleeding (UGIB) is a common medical 
emergency and the annual hospital admission rates vary from 45 - 120/100 
000 persons (69, 81, 139, 171). The proportion of patients admitted with UGIB 
being > 60 years old has steadily increased from 6% -17% in series presented 
during 1921 - 36 to 40% - 48% from 1953 - 73 (2). This trend has further 
progressed also during subsequent years as well, and Rockall presented a 
figure as high as 68% in 1995, (133).  
Peptic ulcer bleeding (PUB) is the single most common cause of UGIB, 
comprising 37%-50% of pa tients with UGIB which is equal to a hospitalization 
rate of 30 - 50/100,000 and year (39,51,67,84,118).  
The true incidence of peptic ulcers is difficult to estimate since not all patients 
with ulcers will seek medical care. Schöön and co-workers reported (140), 1402 
ulcers in 1137 adults during one year (1985) the city of G othenburg with, at 
that time, had an adult population of 360,000. Of the ulcers, 222 presented as a 
bleeding ulce r.. The majo rity o f hospitalize d patients with PUB are men (20, 
107,159) reflecting the sex ratio in peptic ulcer disease in general (140). Gastric 
ulcer patients are generally older than patients with duodenal ulcer, and a 
difference in median age of 10 years was reported by Branicki(18,19).  
Mortality in peptic ulcer disease 
It is estimated that the current death rate, in western countries, due to peptic 
ulcers, is 2 - 4/100 000 (95) based upon death certificate figures. This implies 
that 20 - 30 000 patients die due to peptic ulcers in Europe every year. 
Sweden has a corresponding death rate of 200 - 300 per year. 
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The number of d eaths due to peptic ulcer, i.e. inc luding both deaths due to 
bleeding and to perforation, has, however, declined by more than 50% silice 
1955 (95). The major part of this decline occurred between 1975 and 1984, a 
period during which H2 receptor antagonists (H2RA) were introduced, but a 
causal relationship between use of these drugs and a decline in death rates is 
difficult to substantiate. Data from the US, however, indicates hat only minor 
changes have occurred since 1979 (94). 
The decline in overall mortality due to peptic ulcers is not paralleled by 
reductions in the proportion of the p atients admitted with a PUB that die, i.e., 
the case-fatality rate, which is still as high as 5% - 15%, Table 1. All 
comparisons of case fatality rates are, however, hampered by variations in 
follow-up time. Most authors do not state the follow-up period at all, and 
instead they simply declare that patients were followed until discharge or, 
they present data for a limited period of fo llow-up, say 7-10 days. The vast 
majority of de aths occur among patients who are over 60 years (128) and half 
of the deaths occur during the second half of the month (IV, V and VI). 
Consequently, it is of pi votal importance to report the age profile of p atients 
studied and also to precisely define the length of follow -up, which should be 
at least 3- 4 weeks for all patients. 
The cause of death in patients admitted with a PUB is most often 
cardiovascular events and only rarely due to exsanguination, (47). 
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Table 1. Mortality in studies including patients with PUB. Figures in brackets 
represent the mortality for the subgroup of patients over 60 years. 
Author Year No. of Mortality Follow-up 
patients period 
Schiller (139) 1970 947 6.9% NG 
(12.6%) 
Duggan (43) 1972 830 8.3% NG 
(23.6%) 
Wara (162) 1985 276 10.5% NG 
Collins (33) 1985 2500 5-8% Vary 
Katchinsky (85) 1989 471 10.4% Discharge 
Branicki (20) 1990 701 4.9% NG 
(10.0%) 
Wheatley (164) 1990 342 4% (5.6%) NG 
Daneshmend (39) 1992 503 7.2% 40 days 
Henriksson (67) 1991 592 3.5% 30 dgr 
Walt (259) 1992 1005 5.6% Discharge 
(9.1%*) 
Herold (70) 1994 85 22.3% NG 
Hsu (73) 1994 227 0.9% 10 days 
Vreeburg (171) 1997 379 15% Discharge 
* over 65 years 
Current treatment options 
There are several prerequisites that a treatment must fulfill to become 
efficacious in the treatment of PUB. It should be safe, ideally be effective both 
in stopping the bleeding and preventing rebleeding. Furthermore, it should 
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be easily accessible and possible to use in all patients as well as by all 
hospitals irrespective of the level of expertise and experience and cost 
effective. The ultimate goal is, of co urse ,to reduce mortality, but a reduction 
in the need for intervention in terms of. endoscopic intervention, surgery or 
blood transfusions is also of major importance. 
Since continued bleeding or rebleeding is the event leading to intervention, 
efforts have been focused on reducing their occurrence. 
Stanching the bleeding can either be accomplished by improving the 
physiochemical conditions for hemostasis (i.e., suppress acid or inhibit 
fibrinolysis) or by achieving hemostasis by means of mechanical methods, 
that is, by endoscopic or surgical intervention. 
Acid suppressing agents 
The rationale for the use of acid inhibitory drugs in the treatment of PUB is 
based upon in vitro data showing that hemostatic mechanisms are highly pH 
dependent and that coagulation and stable platelet aggregation do not occur 
at pH levels below 6 (27, 45 , 56). Furthermore, pepsin exerts its maximal 
proteolytic effect at a pH around 2 and gradually decreases to negligible 
activity at pH 5 (10, 131). It is therefore reasonable to assume that for an acid 
suppressing therapy to improve hemostasis, it should have the capacity to 
maintain the intragastric pH at a level of approximately 6 or above. 
Antacids of various potency have been used in the treatment of PUB for many 
years. However, most often in rather low doses and with infrequent dosing. 
Curtis and co-workers, 1973, (38) described the results of aggressive 
administration of a ntacids to patients with massive bleeding from the upper 
gastrointestinal tract. The aim was to keep intragastric pH at 7.0 or above with 
hourly titration and administration of antacids. With this very laborious 
regimen the bleeding was stopped in 23 out of 25 patients (92%). In one of the 
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two treatment failures pH could not be raised above 4.5 despite massive 
instillation of antacids. Two later studies (90, 172) , however, indicated that 
antacids were of limited value. None of them, however, measured intragastric 
pH and the lack of effect could simply be due to insufficient control of the 
intragastric acidity. 
The introduction of Cimetidine, the first histamine-2-receptor antagonist 
(H2RA) in the mid-seventies paved the way for a new era in acid inhibition 
therapy and studies soon erged using this new drug or its later successor 
ranitidine in patients with PUB. An early meta-analysis based on 27 
randomized clinical studies (33) indicated that results were "moderately 
promising" but five years later Langman concluded that "available data, is, 
however, inadequate to establish the usefulness of pharmacological 
measures" (101). The disappointment was further underlined by the results 
from the, up uitil this point of t ime, largest randomized clinical trial in PUB 
patients presented by Walt 1992 (159). This study showed no significant 
reductions in mortality, rebleeding rate or the need for surgery in PUB 
patients randomized to famotidine infusion compared to placebo. 
There are at least two reasons why H2RA may have failed in PUB. Firstly, 
they only competitively block the stimulation of acid secretion mediated by 
the histamine-2 receptors and stimulation mediated by gastrin, acetylcholin or 
other stimuli may still lead to acid secretion. A second reason is a rapidly 
evolving tachyphylaxis which occurs already within 24 hours and rapidly 
leads to decreasing control of intragastric pH (113, 166). The reasonable 
conclusion from these studies is that the concept of profound and sustained 
acid inhibition has actually never been properly tested. 
Omeprazole has a different mode of action and binds, after protonation in the 
highly acidic intragastric milieu and conversion to a sulfenamide form 
strongly to the H'K'-ATPase. This is the final step in gastric acid production, 
the "acid pump" , that is present in the secretory surface of the gastric parietal 
cell. There is a constant circulation between "active" H'K'-ATPase in the 
secretory cell surface and "resting" enzyme in the intracellular tubulovesicles. 
Background 17 
The enzyme can, however, only be blocked in its "active" phase on the 
secretory surface. In the stimulated human parietal cells, it is reasonable to 
assume that about half of th e H'K'-ATPase is present in the secretory surface 
but this figure remains somewhat uncertain (63). The half life of ome prazole at 
the secretory surface is in the range of 1-2 hours; after which it circulates back 
with it s bound H'K'-AT Pase to the tubulovesicles in the cytoplasm (141) .  A  
continuous infusion of omeprazole is therefore necessary to block pumps that 
migrate to the surface if a high degree of blockade is requested. 
The first study with omeprazole given as repeated injections was performed 
by Lind and co-workers (205) who showed profound reductions of acid 
output. Several more studies have later been performed to investigate what 
dose of omeprazole is required to stabilize intragastric pH values above 6. 
Repeated i.v. injections of o meprazole (80 mg + 40 mg + 40 mg + 40 mg over 
24 hours) did not reach these levels (5) but Cederberg could, after a series of 
dose-finding experiments (24, 25), show that a p rimed continuous infusion of 
omeprazole, (i.e., 80 mg given i.v. over 30 min followed by a continuous 
infusion of 8mg/h), maintained stable and high pH values also after a 
pentagastrin challenge. Nielsen and co-workers (123) could shortly thereafter 
show, that the effect was stable up to 22 hours. Corresponding, similar effects 
upon intragastric pH were later demonstrated in duodenal ulcer patients (26, 
89), in patients with PUB (96) and in healthy volunteers during 72 hours 
infusion (122). In contrast to H2RA, no tolerance development has been 
described with omeprazole (113) .  
Based on available data (published and unpublished) it can be concluded that 
the dose 80 mg + 8 mg/h is needed during the first 24 hours to create an 
intragastric pH likely to be optimal for hemostasis. However, no formal 
comparative study has addressed the possibility of a lower infusion dose after 
the initial 24 hours when most acid pumps are likely to be blocked. 
Furthermore, no data exists on the effect that standard oral healing doses of 
omeprazole has on intragastric pH after of these high i.v. doses have ceased. 
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The clinical effects of omeprazole given in a variety of doses and dosing 
regimens have been evaluated in several studies including patients with 
upper gastrointestinal bleeding. Most of t hese studies have reported small or 
no effects. In the largest of these, which was a randomized clinical trial 
including 1147 patients with UGIB (39), omeprazole was administered as 
repeated injections (80 mg + 40 mg + 40 mg + 40 mg) over 20 to 27 hours 
which was followed by oral treatment 40 mg twice daily for three days.. The 
study, however, showed only minor advantages for patients treated with 
omeprazole. Oral administration of omeprazole has also been evaluated in 
patients with PUB (87). This study showed a better outcome for patients in the 
omeprazole group but the results need confirmation. Indian ulcer patients, as 
in this study, are suggested to have a l ower parietal cell mass than Western 
patients (86) which can have influenced the result. 
The present situation is therefore confusing and a number of questions are 
still to be answered before the definitive role of o meprazole in the treatment 
of PUBs can be established. Firstly, we have to identify the dose of 
omeprazole to be given to patients with a peptic ulcer bleeding both during 
the acute bleeding phase and the subsequent ulcer healing phase. Secondly, 
we need to study the effects of this dose regimen upon the clinical outcome 
for patients admitted with a PUB in large randomized clinical studies. 
Antifibrinolytic drugs 
The rationale behind the use of anti fibrinolytic substances in the treatment of 
ulcer bleeding is based on the report of a plasminogen activator in the gastric 
mucosa in patients with peptic ulceration and the finding that free plasmin in 
the gastric venous blood were more commonly detected in peptic ulcer 
patients than in controls (36). A subsequent study, however, challenged 
whether this actually applies to anything but a small subset of pa tients (108) .  
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Henriksson and collaborators (65) showed a normal fibrinolytic activity in 
peripheral blood of PUB patients at admission and the results indicated a 
development of a hypofibrinolytic state the following day. 
The effect of antifibrinolytic drugs has been evaluated in several studies. 
Unfortunately most of these studies have included a rather heterogeneous 
study population (7,11) which complicates the evaluation. In a well designed 
study in which patients with benign bleeding lesions in the stomach and 
duodenum were included, tranexamic acid was given i.v. for three days 
followed by oral treatment for another three days. The authors reported 
reduced blood transfusion requirements and need for emergency surgery 
(147). A meta-analysis of studies performed concluded that tranexamic acid 
may be of value (68) but also emphasizes the lack of definitive trials. Despite 
this efficacy potential, tranexamic acid is not routinely used as a first line 
therapy (126) which may be a result of concerns about adverse events (68,163). 
Somatostatin 
Somatostatin or its more long-acting analogue octreotide has been studied 
separately or in combination with acid reducing agents. Two studies have 
compared somatostatin with H2RAs i.e., Cimetidine or ranitidine and both 
presented better results in the somatostatin group. The studies were 
unfortunately either open (35) or rather small (154) and firm conclusions can 
not be drawn. Other studies could not show any significant benefits in the 
somatostatin treated groups compared with placebo (8,109,145). 
Christiansen (30) reported no significant differences for octreotide versus 
placebo in a well designed study in PUB patients. 
Somatostatin combined with ranitidine was compared with omeprazole 
infusion in one small study (n = 20) (5 2). No significant differences in clinical 
effect could be shown between the two treatment arms. 
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Endoscopic treatment 
The introduction, in 1961, of the flexible endoscope in clinical 
gastroenterology by Hirschowitz (71) suddenly offered a unique diagnostic 
precision in patients with UGIB. Patients' outcome did not, however, change 
significantly despite the use of early endoscopy per se (42, 55, 129). The great 
break-through came with the advent of the possibility of a therapeutic 
intervention directed towards the bleeding source through the endoscope. 
The extent to which therapeutic endoscopy may decrease further bleeding, 
reduce the need for surgical intervention and mortality has been addressed in 
several controlled clinical trials. Injection with sclerosing agents combined 
with adrenaline or adrenaline alone are most commonly used. Other 
techniques include laser coagulation, heater probes or electro coagulation 
(151).  
Recently other endoscopic hemostatic methods have been introduced such as 
the hemoclip and fibrin glue injection. The clip was designed in the mid 1970s 
by Hayashi (62) and later modified by Hachisu (59). Large comparative studies 
are lacking but good results have been presented (13). Fibrin glue was first 
introduced in the mid eighties (57) and in a recent large study promising 
results were presented (70). The method is, however, rather laborious since it 
requires re-endoscopy and further injections until the ulcer base is free from 
stigmata of recent bleeding. 
The results from studies of all these different techniques have, however, often 
been inconclusive or conflicting, possibly because of small sample sizes, 
variable inclusion criteria and differences in patient characteristics. 
The first meta-analysis by Sacks et al (138) included 25 studies in which PUB 
patients had been endoscopically treated and showed a 69% reduction in 
rebleeding, a 62% reduction in surgery and 30% reduction in mortality. 
Cook (34) included 30 randomized clinical trials in a meta-analysis evaluating 
three main types of hemostatic endoscopic therapy ( i.e., thermal contact, laser 
treatment or use of sclerosing agents) in patients admitted due to UGIB. From 
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the 30 studies, 22 presented data for PUB patients. The results showed that 
these treatments, when applied in PUB patients, significantly reduced further 
bleeding by 43% (95% CI ; 15% - 61%) and surgery by 63% (95% CI; 54% -
73%). Also hospital mortality was significantly reduced by 60% (95% CI 52% -
69%). However, only one (149) of t he 22 studies in the meta-analysis showed, 
by itself, statistically significant improvements. This is an important 
illustration of the problems associated with meta-analyses which has been 
thoroughly discussed in several recent articles (3,6). 
In 1991 Swain (152) concluded after a very comprehensive review of d ifferent 
techniques that "the results have provided fairly convincing evidence that 
endoscopic intervention is of value to patients with PUB". 
Mortality after a PUB is not solely confined to the early hospitalization period 
but rather to a period up to 30 days after the initial bleeding (II, III, IV and 
VI). Very few studies have reported the length of follow-up and it is therefore 
not yet clear whether the mortality reduction seen in these meta-analyses 
actually implies a significant higher proportion of patients surviving long-
term or whether the hemostasis achieved only postpones death with the 
patients dying later in a cardiovascular complication. Any long term data on 
this topic is unfortunately not presented. 
Consequently, even though results presented so far are rather promising 
further studies must confirm the benefits of these treatments also outside 
clinics with special interest. Irrespective of which endoscopic treatment is 
used, each mode requires expertise and continued training to be effective. 
In fact, most patients with PUB will not be treated in a referral center with 
devoted and experienced endoscopists available 24 hours a day. Thus there is 
a need for other methods that can be safely and effectively used by all doctors 
at all hospitals in patients with peptic ulcer bleedings. 
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Surgery 
The need for surgery in a patient with PUB has decreased during the last 
decades despite the increasing age among PUB patients.  Gustavsson (58) 
reported a decline in the rate of emergency operations, between 1956 and 
1985, from 16% to 12%. Further decline could be expected after the 
introduction of endoscopic hemostatic techniques as an alternative to surgery 
in patients with rebleedings. The figures presented by Qvist and co-workers 
(232) confirm this, when he reported in 1994 that only 1% of patients needed 
immediate surgery on admission and only 5% in total, in his material of 341 
patients with PUBs. 
The mortality after surgery is highly dependent upon the timing of the 
operation. Those despairing cases where surgery must be undertaken without 
previous endoscopy or blood transfusion still carry a high mortality rate from 
12% even up to 50% (75, 130) . In contrast, early elective surgery (i.e., after 
initial endoscopy with or without endoscopic hemostasis) has been shown to 
carry a lower risk (119,130).  
Recently a prospective study was presented where all PUB patients (n = 253) 
underwent emergency endoscopy and injection therapy (267). In patients 
regarded as being at high risk an early elective operation was performed (n = 
126). The mortality in this group was 9% while no patient died in the non-
operated, low-risk group giving an overall mortality of 4%. 
The indications for emergency surgery in general and particularly the number 
of transfusions that should have been transfused before deciding to operate 
have always been a matter of debate. In a recent study it was suggested that 
besides those cases with an ongoing exsanguinating bleeding, surgery may be 
indicated in elderly patients with an arterial bleeding or visible vessel or 
blood transfusion requirement exceeding 5 units (32). Patients with large 
ulcers in the posterior duodenal wall may also be candidates for surgery due 
to the near proximity to the gastroduodenal artery (32) (83).  
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Due to of effective and safe medical remedies for causal treatment of ulcer 
disease such as Helicobacter pylori eradication or long-term antisecretory 
medication, the operative strategy in a patient with a PUB has now changed 
to a more conservative approach with only ulcer ligation/underrunning the 
bleeding vessel in duodenal ulcers. A more definite surgery is not reasonable 
and should be avoided (136). A higher rebleeding rate seen after simple 
underrunning/excision than after more extensive procedures may challenges 
this statement (93). 
For gastric ulcers an excision of th e ulcer is important. However, in a patient 
in shock, the risk of a difficult excision may be outweighed by an increase in 
mortality or morbidity and in such a case an individual solution may be 
necessary. The same applies to the role of resective procedures which may be 
considered in, for instance, ulcers located high on the lesser curvature which 
are likely to carry a particularly high rebleeding risk since the ulcer is close to 
the left gastric artery (250). 
Risk factors 
It is of special clinical importance to identify those factors which imply a low 
or high risk to a patient with a PUB. Knowledge of th ese factors will offer the 
clinician important guidance tools when setting priorities in a busy 
emergency ward. It will be possible to provide true high risk patients 
intensive care and a rapid start of specific therapeutic measures while low risk 
patients can safely be directed to other ward facilities and even be quickly 
discharged. The most commonly analyzed response variables in this respect 
are rebleeding or mortality. 
Risk factor analyses in PUB patients have been performed in a large number 
of studies. There are, however, several difficulties to be considered when 
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performing such studies. Unfortunately, there are often many deficiencies 
hampering the published studies in this area. 
All risk factors are more or less related to each other and the value of an 
isolated risk factor can depend very much upon other related variables. To 
study, for instance, the prognostic value of a gastric ulcer relative to a 
duodenal ulcer requires that a correction is made for influencing factors such 
as age since gastric ulcers are more common among elderly, age is therefore a 
so called confounder. If this correction in the analysis is not made, it is 
impossible to separate the prognostic value of the gastric ulcer from that of 
higher age. A multiple logistic regression analysis takes into account all 
variables in the model and thereby compensates for influence by the other 
factors when the prognostic value for a certain factor is calculated. This 
contrasts to the univariate logistic regression which analyzes the value of a 
certain variable without compensation for other confounding factors. 
Consequently, a univariate approach cannot give any reliable estimate of the 
true value of a single variable unless only one risk factor is operating. Most 
studies in this area have still used this approach. 
In analyses of prognostic factors for mortality, factors like rebleeding, blood 
transfusions and the need for surgery have often been included in the models 
(20,155). This is problematic since these factors are actually response variables 
observed during the course of events and as such cannot be seen as true 
independent prognostic variables. They may predict a less favorable outcome 
but it is not possible to study their prognostic value without specifically 
designed studies. 
It is of crucial importance that the data to be analyzed for prognostic 
importance represents the true situation. To collect valid information, under 
emergency conditions, from an elderly and possibly exsanguinated patient 
with respect to current medication and medical history is by necessity almost 
impossible. If s uch variables are to be analyzed, a carefully designed study 
with prospective collection of data must be performed. Other data such as, 
age and sex can also safely be collected in other types of studies while data on 
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therapeutic procedures, blood transfusions and blood pressure at admission 
represent an intermediate group. 
Most commonly reported risk factors for mortality have been: age over 60 (65) 
years (20, 78, 82) and signs of recent hemorrhage at endoscopy (134, 255). 
Corresponding risk factors for rebleeding are: shock (17, 20) and stigmata of 
recent hemorrhage (17,21). 
The Forrest classification (46), Table 2, has frequently been used in attempts to 
ascribe a certain Forrest class a high or low risk of rebleeding and mortality. 
The problems with a large inter-observer variation has recently been shown 
(98,103) and this may partly explain the differences in reported results. 
Table 2. The Forrest classification 
Active bleeding Spurting Forrest la 
Oozing Forrest lb 
Recent bleeding Visible, non-bleeding vessel Forrest IIa 
Adherent blood clot or black base Forrest lib* 
No bleeding Lesion with no stigmata of bleeding Forrest III 
* A Forrest lie class has also been suggested (ulcers with black base). 
In summary, although there are quite a few publications in this field, data are 
of poor quality and further studies comprising high quality data are needed to 
provide the clinicians with true guidance tools. 
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AIM OF THE PRESENT STUDY 
Several questions remain to be answered regarding the treatment and 
prognosis of patients with peptic ulcer bleeding as illustrated by the given 
review. The aim of the present study was therefore to address the following 
questions: 
• What intravenous infusion dose of omeprazole should be used to ensure an 
increase of intragastric pH to levels alleged to ensure hemostasis during the 
first three days of treatment days for a PUB? 
• What oral dose regimen of o meprazole should be used subsequent to the 
infusion period in order to ensure healing of the ulcer based upon 
intragastric pH observations? 
• Is omeprazole, if administered as above, effective in high risk patients with 
a PUB to reduce continued bleeding, prevent rebleeding and decrease the 
need for therapeutic intervention? 
• What is the short and long term mortality after admission for a PUB and 
how does it relate to mortality among matched controls? 
• What risk factors can be defined for recurrent bleeding, short and long 
term mortality in patients admitted with a PUB? 
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PATIENTS AND METHODS 
Study I 
The aim of this study was to identify the intravenous infusion dose of 
omeprazole that increases the intragastric pH to levels alleged to ensure a 
durable hemostasis during the first three days of a PUB. Furthermore, to 
identify an oral dose regimen of omeprazole to be used subsequent to the 
infusion dose regimen in order to ensure that the ulcer heals. 
Since most rebleedings occur during the first three days of admission (118)  it 
was decided that the infusion should continue for three days and after that an 
oral dose regimen should start. 
Based upon published and unpublished data we were convinced that a 
primed continuous infusion of 80 mg + 8 mg/h was needed to keep 
intragastric pH at levels alleged to be sufficient for hemostasis during day 
one. Consequently, it was decided to study whether it was necessary to 
continue with the infusion of 8 mg/h also after the first 24 hours as well or if 
it was possible to reduce it to 4 mg/h or 2 mg/h and still keep intragastric pH 
at requested levels. 
A reference level during the infusion period was set at pH 5.4 based on in 
vitro data on coagulation and platelet aggregation (27, 45, 56). The 
corresponding reference level for the healing phase with oral dosing was pH 
3. This was based upon data from compilations of results from clinical 
studies using different dosing regimens with various pH increasing potency 
(23, 72, 76). These studies have suggested that if the intragastric pH is kept 
above pH 3 for more than 75% of the day a predictable and high healing rate 
of both gastric and duodenal ulcers are reached. 
The true target population for therapy with these intravenous doses of 
omeprazole in these doses is patients with an acute PUB. It has, however, 
been suggested that patients with an acute PUB may, in circumstances of 
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acute bleeding, actually have a reduced acid production. Chandler, ( 2 8 )  
described a low acid output in patients shortly after admission with a PUB 
and Fullarton (48) showed that gastric acid secretion was reduced by 
intraduodenal infusion of autologous blood in healthy volunteers. Since we 
wanted to test the possibilities of a dose reduction under "worst scenario" 
conditions but still in a population, mimicking the actual target population as 
much as possible, we chose to include duodenal ulcer patients in remission. 
Consequently, 12 H. pylori (+) patients were included and they all received 80 
mg + 8 mg/h during 48 hours. In a subsequent experiment, with the same 
group of patients but separated from the first with at least 14 days, 
omeprazole infusion 80mg + 8 mg/h was again given but only during the first 
24 hours whereupon six patients were randomized to a subsequent dose of 4 
mg/h and the other six to 2 mg/h during the period 24 - 48 hours. Intragastric 
pH was measured continuously during the 48 hour periods. 
Later, data emerged to indicate that intragastric pH may be different in H. 
pylori (+) than in H. pylori (-) individuals after omeprazole administration 
(9). Consequently, in part two of the study, where the aim was to find the 
optimal oral dose to be used after the first 3 days of intravenous infusion, we 
included 12 healthy, H. pylori (-), volunteers. These subjects received 
omeprazole 80 mg + 8 mg/h during 72 hours after which they were 
randomized to either omeprazole 20 mg o.d. or b.i.d. Intragastric pH was 
measured continuously during days2, 3, 4, 6 and 10. 
All intragastric pH measurements were made using the Gastrograph Mark II, 
(MIC AG, Solothurn, Switzerland), a well validated and recommended data 
logger (253). The electrodes were of bipolar glass design (Ingold, Urdorf, 
Switzerland) with high accuracy and widely used for intragastric pH 
measurements (50). The electrode was calibrated using the Gastrograph® 
standard buffers at pH 1.7 and 7.0 and was positioned in the stomach by 
inserting it slowly until a clear drop in pH readings was seen after which the 
electrode was withdrawn just enough to again record neutral pH. From that 
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position the electrode was further inserted 8 cm which is approximately 10 cm 
below the lower esophageal sphincter. 
From the collected pH data we calculated a mean pH for each group based 
upon the (12)24 hour median pH values from each individual which is in 
agreement with current recommendations (237). Furthermore, since our 
specific interest was to study how various dose regimens influenced the time 
with pH levels over 5.4, the mean is a rather insensitive variable and therefore 
the fraction of time (%) with pH above 5.4 was also calculated. 
According to Merki (224) the intra-individual day to day variation of pH, as 
currently assessed, is minimal and the reproducibility good if food intake and 
daily activities are standardized. The reproducibility of variables such as 
"fraction of time above pH 5.4" has, however, not yet been fully tested. 
Studies II, and III 
Studies II and III were performed in parallel and with very similar protocols. 
In both studies we chose to include patients with an acute PUB in the stomach 
or duodenum with ongoing or signs of recen t bleeding (that is Forrest I or II), 
Table 2. Furthermore, patients should have a high risk of rebleeding and 
death. 
Thus two risk groups were chosen which were; patients over 60 years of ag e 
(II) and patients with hemodynamic instability (III), 
Patients 
The following inclusion criteria applied for Study II: 
Patient's age > 60 years, current melena or hematemesis (starting less than 48 
hours before admission), endoscopy performed within 12 hours of admission 
showing a peptic ulcer in the stomach or duodenum classified as Forrest la, 
lb, Ha or lib. 
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The following inclusion criteria applied in Study III: 
Patient's age above 18 years, current melena or hematemesis, endoscopy 
performed within 12 hours of admission showing a peptic ulcer in the 
stomach or duodenum classified as Forrest la, lb, Ha or lib and clinical signs 
of circulatory stress or blood loss (at least two of the following three 
conditions had to be fulfilled at least once during the time span from 
presentation of the UGIB until the endoscopy): Systolic BP < 100 mm Hg, HR 
> 100/min or B-Hb < 7.0(men), 6.5(women) mmol/1. (Conversion factor to g/1 
- x 16.1). 
The main exclusion criteria applied in both studies (II and III) comprised: 
gastrointestinal malignancy, esophageal varices, Mallory-Weiss syndrome, 
intake of anticoagulants during the last five days/last week, deficient 
hemostasis (simplastin < 40% or platelet count < 100 x 10'/1 or similar) severe 
concomitant disease reducing life expectancy to less than 6 months/ making 
study compliance questionable. 
The assignment of treatment was made according to computer-generated 
randomization lists. The lists were made separately for each centre and within 
blocks of 2 consecutive patients. This block-size was only known by the 
statistician. 
Methods 
In both studies administration of s tudy medication started within 30 min of 
the endoscopy. Omeprazole (or matching placebo) was given as a bolus 
infusion, 80 mg over 30 min, followed by start of an intravenous infusion of 8 
mg/h,which was continued for a total of 72 hours wherafter all patients 
received oral treatment, omeprazole 20 mg once daily. 
Mannitol was used as a placebo since it has an identical appearance to the 
omeprazole formulation and has no known therapeutic effects in these doses 
(80 mg of omeprazole resembles 40 mg mannitol in volume and appearance). 
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In Study II no endoscopic intervention was allowed except in ulcers classified 
as Forrest la. Consequently, patients with ongoing bleeding (Forrest lb) could 
also be studied. In Study III endoscopic hemostasis was the main aim in all 
Forrest I patients. Forrest IIa ulcers should also be treated. In case of 
endoscopic intervention, injection techniques should be used as the first 
alternative. 
The treatment effect was, according to the protocol, evaluated after the 
infusion was stopped, which was after 3 days. A safety follow up was done at 
day 21. The primary variable in both studies was a composite, ordinal scale, 
variable which classified the outcome for each patient from worst to best as 
follows: 
5) death, 4) surgery, 3) additional endoscopic treatment, 2) > 3 units of blood 
transfused, 1) 0 - 3 units of blood transfused. By using this systematic 
characterization we obtained an overall evaluation of the treatment effect and 
avoided the problem of counteracting effects between efficacy variables 
always ranking the patient according to worst outcome. In Study II, the 
number of transfused blood units was also analyzed as a primary variable 
while it was a secondary variable in Study III. Other secondary variables 
were: degree of bleeding, duration of bleeding, need for surgery, need for 
additional endoscopic treatment and mortality. Degree of bleeding was 
evaluated every 12 hours and reflected the worst degree of b leeding during 
the 12 hour period preceding the evaluation. Duration of bleeding was 
defined as the number of s uch 12 hour periods with bleeding, (maximum 6 
periods). 
Rebleeding was not included as an efficacy variable. Even if this variable 
allows comparisons between studies, these may often be misleading due to 
inconsistent definitions both from a quantitative and qualitative point of vie w 
in different studies. 
An independent, external statistician, was responsible for sequentially 
monitoring mortality in both studies. The Steering Committees for the studies 
should only be informed if there was a concern for safety. 
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The sample size calculations for both studies were based upon the number of 
blood units transfused. The assumption was to detect a reduction of blood 
transfusions by one-third in the omeprazole treated groups, established with 
a power of 80 % and the risk of false significance less than 5%. Depending 
upon slightly different assumptions for the relation between the mean and 
standard deviation of the number of transfused blood units, the calculations 
resulted in a sample size of 400 patients in Study II and 350 in Study III. 
Study IV 
This study was performed to generate data to form hypotheses to be further 
tested in Studies V and VI and also to substantiate the findings from Studies II 
and III. The study was conducted as a retrospective cohort study in patients 
aged 60 years or older who had been hospitalized at Sahlgren Hospital or 
Östra Hospital in Gothenburg for a peptic ulcer bleeding during a five years 
period, 1 January, 1989 to 31 December, 1993. The following discharge 
diagnoses were included (International Classification of D iseases, revision no. 
9, codes 531, 532, 533 and 534 with subgroups -0,-2, -4 and -6 (that is , 
chronic or acute gastric, (pre)pyloric, duodenal, peptic, gastrojejunal, stomal 
or anastomotic ulcers with bleeding). Patients, experiencing a peptic ulcer 
bleeding during their stay in hospital due to other diseases or in whom the 
bleeding came from a stress-induced ulcer were excluded after the hospital 
records had been reviewed manually. 
Given the retrospective design of the study we primarily collected data which 
we considered to be accurate and not hampered by this design. The data 
collected concerned age, sex, ulcer site, number of transfused blood units, 
subsequent treatment (that is operation, endoscopic treatment or 
pharmacological treatment only) and length of hospital stay. Other data, such 
as Forrest class, presence of hemorrhagic shock on admission, past or present 
diseases and current medication that could potentially influence healing, 
(such as non-steroidal anti-inflammatory drugs, aspirin, or anticoagulants) 
Patients and methods 33 
were also collected but was evaluated with caution due to the retrospective 
study design. 
The hospital records were also scrutinized for any rehospitalization due to a 
recurrent bleeding during the 90 days after the index bleed. This cut-off level 
was chosen arbitrarily. 
The hospital records of 676 of the 687 patients who fulfilled the inclusion 
criteria could be located and were subsequently reviewed. 
A review of all patients with respect to survival was carried out by 31 
December, 1995 using the Swedish National Population Register and the 
follow-up period was therefore from two to seven years. 
A traditional control group should contain individuals free from the disease 
under study. It is, however, practically difficult to find a group that is 
virtually identical to study cohort except for peptic ulcer bleeding. To 
circumvent this problem we identified, from the same geographical area, a 
comparatively high number of controls (n=9464) which equaled 14 control 
individuals to each patient. The controls were matched according to age and 
sex by using the Swedish National Population Register from 1980. Survival 
data for the controls during 1980 - 1986 was obtained from the Population 
Register and these were compared with survival data from our patients. 
Given the relatively low occurrence of peptic ulcer bleeding in the population, 
< 1/1000/year, it can thus be estimated that among the controls less than 9 
PUB occur during one year which is l ess than 63 during the seven years of 
follow up. It is therefore reasonable to believe that the impact of these 
individuals, representing a fraction of a bout 6%o, is negligible when studying 
survival in the whole control group. Following the controls during a different 
time period (1980 - 86) than the cases (1989 - 95) can infer a problem. In this 
case the population in Gothenburg did not show any significant 
demographic/survival changes between 1980-86 compared with 1989-95 
based upon data from National Statistics (Statistiska Centralbyrån, Sweden) 
(146) and this is thus not likely to influence the conclusions. 
34 Patients and methods 
Multiple logistic regression analyses were performed including the variables 
collected and listed above. Analyses included possible influence upon short 
and long term mortality, as well as rehospitalisation due to rebleeding within 
90 days of ad mission. The multiple logistic regression analyses are described 
on page 40. 
Study V 
This study included a subset of patients from Study II and III (that is, the 
patients over 60 years). While Study II and III evaluated the therapeutic effect 
of om eprazole in two well defined risk groups of pa tients with PUB, Study V 
analyzed which factors had prognostic importance for short term survival and 
rebleeding. The cut-off point for rebleeding was set at 3 days (72 hours) since 
less than 10% of rebleedings occur after this point in time (118). The cut-off 
point for mortality was 1 month (30 days) based upon experience from Study 
II, III and IV. 
Merging of data from two separate studies must be done with caution. In this 
case it was considered scientifically valid and correct due to the following 
facts: 1) Both studies (II and III) were performed during the same time period. 
2) The protocols were almost identical. 3) There was no reason to believe that 
patients in one study would respond differently from patients in the other 
study. 4) The difference between centres within each study was likely to be 
larger than the average difference between the two studies. 5) "Study" was 
included as a prognostic variable in the analysis and had no prognostic value 
(OR=0.99). 
Study V th us recruited patients with a peptic ulcer bleeding (PUB) admitted 
to 63 hospitals in Sweden, Denmark, Holland, France and Norway. Eligible 
patients should have been included previously in Study II or III and, 
furthermore, to be included in Study V, also be over 60 years of age. 
Patients and methods 35 
From a total of 587 patients in the two parent studies, 508 patients met the 
current inclusion criteria and were consequently included. Six patients had 
incomplete data sets and were not included in the multiple logistic regression 
analyses (one of them died). 
Table 3 displays the variables that were ' included in the multiple logistic 
regression analyses. Even though it could have been interesting to separate, 
for instance the prognostic value of angina from that of a myocardial 
infarction during last month, we chose to limit the number of variables 
included in the analyses. The risk of both false correlations by chance and 
very wide confidence intervals could thereby be reduced. One common 
variable, "coronary heart disease", was thus created including angina, 
congestive heart failure or myocardial infarction. "Diabetes" was defined as 
need for insulin or oral antidiabetic drugs. " Intake of ASA/NSAID" reflected 
intake during the last two weeks prior to admission. Daily intake of l ess than 
250 mg ASA was not included in this variable . 
Table 3. Variables included in the multiple logistic regression in Study V. 
Category variables 
Shock at admission 
Ulcer localization 
Forrest class (la, lb, IIa, IIb) 
Previous ulcer history 
Sex 
Current smoker 
Diabetes' 
Coronary heart disease^ 
Intake of ASA/NSAID3 
Chronic obstructive airway disease 
Study drug 
Continuous variables 
Age 
Systolic blood pressure on admission 
(mm below 100) 
u
'
3 For definition see text. 
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Study VI 
The aim of this study was to study risk factors for short term mortality in a 
different cohort than in Study IV and V. The General Practice Research 
Database (GPRD) was selected for this study since it is a large, well validated 
and population based. This base is currently the most widely used European 
data base for pharmacoepidemiological research (49). 
The base was started in the late 1980s, by VAMP Health, a commercial 
company, which on a commercial basis started to install computer systems in 
general practioners' (GPs) offices throughout UK. It was predicted that such 
collected data could be used for both administrative and research purposes. 
Since 1994, the acquired information belongs to the UK Department of Health 
and is maintained by the Office of Na tional Statistics in UK. Until now about 
1500 GPs participate in this system covering a population in excess of three 
millions. The data base contains computerized information on demographics, 
details of every visit to the GP, referrals, summaries of specialists' clinical 
notes, discharge letters, results of lab tests and a free text section. 
Prescriptions issued by the GP are directly generated from the computer 
ensuring a complete record of all prescriptions. 
The base is very well validated and covers all segments of the UK population 
both from a geographical as well as from a social point of view and has 
hitherto been the data source for more than 60 publications (49). 
We identified in the GPRD patients aged 30 to 89 years who had been 
admitted to hospital for an episode of upper gastrointestinal bleeding 
between January 1991 and March 1994. Patients had to be free from cancer, 
esophageal varices, cirrhosis, Mallory-Weiss syndrome and intestinal vascular 
abnormalities. The computerized patient profiles of these patients (n=3953) 
were automatically reviewed to include only patients in whom a peptic ulcer 
in the stomach or duodenum was the cause of bleeding. Furthermore, patients 
with one or more of the following conditions were excluded: patients with 
hemorrhagic gastritis or duodenitis only, patients with perforated peptic ulcer 
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and patients experiencing their bleed while hospitalized for other causes. 
After this revision, 1070 patients with an episode of peptic ulcer bleeding 
involving the stomach or duodenum, remained in the cohort. In 772 of th ese 
patients data was partly missing or insufficient and questionnaires were sent 
out to their GP asking for further information. Replies were received from 716 
of t hese and based on this complementary information 50 more patients had 
to be excluded due to violation of any of the selection criteria above. 
Consequently, our final study population comprised 1020 patients. 
Table 4 lists all variables included in the final Cox proportional hazard 
analysis for influence upon mortality. Given the nature of our data source, use 
of non prescribed drugs, for instance, aspirin purchased over-the-counter 
(OTC) was not included as current intake. 
In the final presentation of the relative risks (RR) for the variable of i nterest 
adjustments were only made for age, sex and the variable of interest. This was 
decided upon after an initial analysis including all variables in Table X where 
it was found that the major modifiers of risk were age and sex. Including only 
these factors (+ the variable under analysis) in the final model increased the 
precision of the RR estimate. 
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Table 4. Variables included in Cox proportional hazard analysis for influence on 
mortality within one month of admission. 
Variable Categorization Comment 
PU antecedent Yes Included PU or PUB 
No 
Age 30 - 59 years 
60 - 69 years 
70 - 79 years 
80 - 89 years 
Sex Male 
Female 
Ulcer site Gastric/pyloric 
Duodenal 
Gastric and Duodenal 
Undiagnosed 
Co-morbidity Yes Cerebrovascular, cardiovascular, 
No respiratory or diabetes 
Surgical treatment Yes 
No 
Acid suppressing None 
drug use Current Prescription within 60 days 
Past Prescription > 60 days 
Aspirin use None Incl OTC use 
Current Prescription within 60 days 
Past Prescription > 60 days 
NSAID use None Incl OTC use 
(excl. ASA) Current Prescription within 60 days 
Past Prescription > 60 days 
Alcohol consumption < 2 units/week 1 unit = 8 -10 g (142) 
2-15 units/week 
>15 units /week 
Body Mass Index <25 kg/m: 
25-30 
>30 
Smoking None 
Current smoker 
Past 
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RISK FACTOR ANALYSIS (IV, V, VI) 
Variable selection 
Causes of diseases or events are studied with the objective to explain and 
eventually prevent the occurrence of the event. Commonly, a causal relation 
can be said to exist if the probability of a particular outcome would be 
different in the absence than in the presence of a factor (l). Several forms of 
co-variation between two factors, A and B, can exist. Such a co-variation can 
arise in two different ways (given that A occurs before B). 
1) A causes B 
or, 
2) A and B have the same, common cause (X) 
In alternative 1) a true causal association exists between the risk factor 
(prognostic factor) A and the factor (in this case, event) B while in alternative 
2) the co-variation between A and B is not causal but called a "confounding" 
co-variation. If th e ultimate aim is to reduce occurrence of t he event B, it is 
essential to distinguish between alternative 1) and 2) since it is only by 
eliminating factor A in an association of t ype 1) that an event rate (B) can be 
reduced. 
In the current investigation the aim was to identify factors that are true risk 
factors for death and that they, if e liminated or reduced, should ultimately 
reduce death rate. Those risk factors must therefore be of category 1) as 
indicated above. 
Rebleeding, blood transfusions and surgery, in this context, all fall into 
category 2) since they, together with death, all have a common cause, namely 
bleeding. Consequently, factors of this type were not included in the analyses. 
Still surgery, for instance, can have an association to mortality of type 1). 
However, to be able to investigate this, studies strictly randomizing patients 
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to either operation or no operation must be done. Such designs raise justified 
ethical concern. 
Statistical models 
In the present investigation mortality has been a factor for which we have 
tried to find the true risk factors. It is likely that mortality depends upon 
several variables and not only upon a single one. It can also be assumed that 
there is a co-variation between certain explanatory variables. It is, for instance, 
well known that patients with gastric ulcers are older than patients with 
duodenal ulcers (18,19) and NSAID intake is more common among the lderly. 
Consequently, an analysis of ri sk factors must include all factors of in terest in 
the model (a multivariate approach) to compensate for this co-variation 
between variables and not just take one factor at a time into consideration (a 
univariate approach). To analyze such complex relations a multiple logistic 
regression model (91) is often used which is based on a logistic function, 
Figure 1 . The following logistic function is used: 
f(z)
- TT?7 (I> 
This function has, for several reasons, gained a lot of popularity. It has a 
range, 0 < f(z)<l, for all values of 2. Thus we can never get a risk estimate 
above 100% or below 0% in contrast to, for instance, a linear multiple 
regression model. This is appealing in our perception of the term "risk". 
Furthermore, the S-shape of th e logistic curve; first a minimal risk after which 
the risk increases more rapidly and then levels off and remains extremely 
high once z gets large enough. This is in agreement with a common 
perception of risk influence. 
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Figure 1. The logistic function representing the risk, f(z), as a function of the risk 
index, z. 
The variable, z, is an index that combines the explanatory variables X,, X2,... 
Xk (that could, for instance, be age, duodenal ulcer or shock) according to the 
following formula 
z = a + ß,X ,+ ß2X2 + ...+ßkXk (2) 
where a is a reference constant and ß, to ßk represent coefficients. 
These represent the weight of the individual variables X,, X2,... Xk in the 
overall risk index, z. The values of these coefficients are calculated by a 
method called "maximum likelihood" using data from a study in which the 
outcome is known for each patient. However,to describe this technique is 
beyond the scope of this presentation. 
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The relative risk ratio (RR) can then, in principle, be calculated for each risk 
variable in the model by dividing the value for f(z), including the explanatory 
variable under study, with the value of f(z) when this variable has been 
omitted but all other factors are kept constant. If, for instance, we want to 
calculate a RR of dying a smoker relative a non-smoker, the f(z) for the 
smoker is divided by f(z) for the non-smokers 
The problem with using a RR is that the level depends upon the level of other 
risk factors in the particular patient. This means that if we are interested in the 
RR for mortality for a smoker versus a non-smoker the resulting RR value for 
a 60 year old smoker will be different to that of a 61 year old smoker. 
However, if the formulas (1) and (2) above is used to calculate an OR 
instead,the value for smokers will be the same for all smokers regardless of 
their age and also independent of the values of other prognostic values. This 
is often appealing. This calculation is a complicated process which will use the 
values of a and ß in the formula (2) above. 
When the patients in a population are at low risk, say below 20%, the relative 
risk associated with a particular variabel (for instance smoking) only varies 
slightly with other factors , for instance, age. In this situation it is reasonable 
to approximate the RR with the OR. 
To correctly estimate a RR for a certain variable we must have outcome data 
from a follow-up study. If the values of one or more risk factor are missing for 
a certain patient this patient cannot be used when the RR or OR are 
calculated. This may cause a bias if the reason for the missing data is 
associated with the outcome of the patient. The results from the analyses can 
be questioned if a substantial proportion of patients has missing data. 
The more complicated Cox hazard regression model used in Study VI and in 
the long term analysis of mortality in Study IV, takes into account not only the 
presence or the absence of an event (i.e., the patient being dead or alive at end 
of st udy) but also the follow-up time for each individual patient. Cox hazard 
regression models present the results in terms of RR. A RR calculated from a 
Cox hazard regression gives, in contrast to RRs based upon multiple logistic 
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regression analyses, a value that is independent of the value of other risk 
factors. (See example above.) 
As a consequence, the numerical values of an OR (or RR) based upon a 
multiple logistic regression model can not be compared with a RR value 
obtained from a Cox regression model. 
Although not used in this thesis, an OR or RR can also be analyzed from a 
simple 2x2 table as illustrated in Figure 2. This is, by far, the commonest 
calcualation behind ORs or RRs presented in the PUB literature. However, if 
more than one variable could have an impact upon the outcome these results 
may be grossly misleading due to confounding caused by other variables. 
Nevertheless, the method is often used, even in modern analyses and it is 
important to identify the method behind the figures presented in order to 
evaluate their validity. 
Factor present 
Yes No 
Yes a b a + b 
Outcome 
No c d c + d 
a + c b + d 
a a 
OR = b 
c 
b + d d 
Figure 2. Methods for calculating OR and RR based upon a 2 x 2 table, a, b, c, d 
denotes number of patients in each cell. 
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RESULTS AND COMMENTS 
Control of intragastric pH (Study I) 
Administration of o meprazole as a primed continuous infusion (80 mg given 
over 30 min followed by infusion of 8 mg /h) resulted in a rapid increase of 
intragastric pH in all patients. The focus of interest in this part of the study 
was the possibility of a decrease of the dose after the first 24 hours. 
Consequently we chose not to include the first 12 hours of the 0-24 hours 
period in the comparisons of results achieved on the 8 mg/h dose and the 
subsequent doses, administrated during 24 - 48 hours. 
The mean pH during the 12 - 24 hour period after start of the study drug 
administration was 6.7 and the mean fraction of t ime with pH above 5.4 was 
92%. During the second day (24 h - 48 h) mean pH was 6.1 and mean fraction 
of time with pH above 5.4 was 90%. Nine of the 12 subjects maintained or 
increased their fraction of tim e above pH 5.4 during day 2 compared with the 
preceding 12 hour period. There were, however, three patients who had a 
decrease, Figure 3. 
The patients were also, in a second experiment, randomly allocated to a 
decrease of the infused dose of omeprazole from 8 mg/h given during the 
first 24 hours to either 4 mg/h or to 2 mg/h for the subsequent 24 hour 
period. All of the six patients randomized to a dose reduction from 8 mg/h to 
4 mg/h maintained the mean fraction of time with pH above 5.4 as did four of 
the six patients randomized to a dose of 2 mg/h. The mean pH in the 4 mg 
and 2 mg/h group was the same (6.1 and 6.2 respectively). 
It should be noted that all subjects, received a high energy liquid oral 
nutrition after the first 24 hours, which may be one reason why a few patients 
reduced their fraction of time with pH above 5.4 on day 2. There was, 
however, virtually no difference in mean pH between the three different 
Results & Comments 45 
dosing groups. Also with respect to fraction of time with pH below 4 there 
were small differences; (2 mg/h - 2%, 4 mg/h - 3% and 8 mg/h - 0.6%). 
These results are difficult to interpretate. The mean pH in the three groups 
did not differ at all and this could indicate that the true differences between 
the doses were marginal. Also the differences were small with respect to the 
patients' fraction of time over pH 5.4. However, in the 8 mg/h dose group 
there were two patients who increased the fraction of time with pH above 5.4. 
This was not seen in any of the other two dose groups indicating a possible 
advantage of the 8 mg/h regimen in those patients who have a sub-maximal 
response during day 1. There was also three patients who, when on 8 mg/h 
day 2, decreased their fraction of time above pH 5.4. To further complicate the 
interpretation these three patients kept their fraction of time above pH 5.4, 
when they received a lower dose, 4 mg/h during day 2. It is possible that all 
three tested doses are on the flat part of the dose response curve. 
The conclusion is that decreasing the infusion dose to 4 mg (or 2mg/h) may 
be as effective as continuing on the 8 mg/h dose. Until further data is 
available, the most secure alternative seems to be to recommend the 8 mg/h 
dose of omeprazole. 
It may be surprising that such high doses are needed to achieve the desirable 
pH levels. In that respect it should be noted that increasing pH from 2 to 7 
implies in fact a 99.999% reduction of th e acid concentration. This means that 
virtually all acid pumps must be blocked. The bolus dose of 80 mg is needed 
to block all available pumps on the surface of the parietal cell but the short 
plasma half life of omeprazole, approximately 40 min, implies that pumps 
coming up to cell surface during subsequent hours are not blocked if 
omeprazole is not administered as a continuous infusion, ensuring a 
sufficiently high omeprazole plasma concentration to block these pumps. 
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Figure 3. Comparison of fractio ns of time with pH above 5.4 during 12 - 24h (when 
all subjects received 8 mg/h) and subsequent interval (24 - 48h - when the subjects 
received 2, 4 or 8 mg/h) 
In part II of Study I all individuals received the same dose regimen (80 mg + 8 
mg/h) during the first three days. Intragastric pH data from day 2 shows that 
this group of healthy H. pylori (-) subjects had almost identical intragastric 
mean pH, 6.3, and mean fraction of t ime with pH above 5.4, 92%, on day 2 as 
the H. pylori (+) patients in part I of the study (6.1 and 90%, respectively). 
Since the study was not designed to make a formal comparison between H. 
pylori (-) and H. pylori (+) subjects no firm conclusions can be drawn but the 
results do not support the suggestion that there should be a difference in 
resulting intragastric pH between infected and non-infected subjects (97) after 
omeprazole administration, at least not in this dose range. 
On day 3, while still infusing 8 mg/h, we noted a reduction of the fraction of 
time with pH above 5.4 from 92% (day 2) to 75%. The mean pH decreased 
slightly from 6.3 to 6.0. It could be seen from the individual pH graphs that 
the decrease in pH was closely related to food intake. During this particular 
study day, the subjects was given a normal diet and these provisions may 
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have contained acidic components which could explain the reduction in 
fraction of t ime with pH above 5.4. 
In previous studies with intragastric pH measurement up to 72 hours it has 
been shown that omeprazole, in contrast to H2-receptor antagonists, 
maintains a potent antisecretory efficacy without development of t olerance or 
decreased effect even during intake of liquid nutrients (92, 113, 122). 
Consequently, we interpret the decrease in fraction of time above pH 5.4 on 
day 3 as an effect of food intake and not as a sign of drug tolerance. 
After cessation of the infusion at 72 hours and start of oral dosing of 
omeprazole we noted, as expected, a gradual drop of intragastric pH. 
Fraction of 
100 -i 
80 -
60 -
• Baseline 
Intravenous infusion 
— 2 0  m q  o d  
—A— 20 mq bid 
2 4 6 8 10 
Time (days) 
Figure 4. Mean fraction of time (95% CI) with pH above 3.0 before and during 
intravenous (days 1-3) and oral (days 4 -10) dosing with omeprazole. The difference 
between the oral doses reached statistical significance during all individual study 
days (p<0.05). 
Intragastric pH stabilized in both dose groups (i.e., the 20 mg once or twice 
daily groups) between day 4 and day 6 with no further changes to day 10 , 
Figure 4. No signs of rebound phenomenon were seen after the omeprazole 
infusion ceased. 
40 -
20 " 
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0 
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The 20 mg once daily dose of omeprazole gave a stable reduction of the 
fraction of time with pH above 3 of approximately 72% which is a level 
considered sufficient for both duodenal (23) and gastric ulcer healing (72, 76). 
The corresponding figure for the twice daily dose was 91%. Consequently, 
there seems to be no reasons to recommend a subsequent twice daily oral 
treatment regimen in this patient population after the three day infusion of 8 
mg/h has been stopped. 
Omeprazole infusion in peptic ulcer bleeding (Study II and III) 
Patient description 
In Study II, the 20 centers in Sweden and the 9 centers in Norway, 
randomized 333 patients. Of these 322 could be included in the intention to 
treat analysis. The remaining patients were either not given any study 
medication at all (n = 4), given unknown study medication (n = 4) or did not 
fulfill inclusion criteria (n = 3). 
Log-books, intended for recording the reasons for not including a patient 
admitted due to a PUB, were distributed to all centers and they could be 
evaluated in 16 of th e 29 centers, Table 5. The other centers were only able to 
provide intermittent and scattered information. 
This table gives valuable information regarding the accuracy by which the 
results from the study can be generally applied to the overall target 
population. Most patients with PUB who fulfilled the inclusion criteria were, 
in fact, included. This information consequently suggests that we have no 
reason to believe that our criteria for exclusion should limit the general 
applicability of the results. 
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Table 5. Patients admitted with PUB during the inclusion period but not enrolled by 
reason. 
Reason for not including a patient Number % of total 
Inclusion criteria not fulfilled 
Age 60 or over 5 2% 
Bleeding within 48 hours of admission 25 11% 
Peptic ulcer, Forrest I or II, in stomach or duodenum 28 13% 
Informed consent 13 6% 
Exclusion criteria fulfilled 
Ulcer of Forrest type III 46 21% 
Severe disease making study compliance questionable 19 9% 
Anticoagulation therapy within 5 days of admission 11 5% 
Phenytoin medication 1 0.5% 
Upper gastrointestinal malignancy 3 1% 
NSAID intake that could not be withdrawn 8 4% 
Omeprazole intake within 5 days of admission 23 10% 
Other reasons 
Endoscopy performed > 12 hours of admission 23 10% 
Need for immediate surgery 2 1% 
Other reasons 14 6% 
TOTAL 221 100% 
The patients' demographic and baseline characteristics were similar between 
the omeprazole and placebo groups with the following exceptions: the 
number of patients with hemoglobin lower than 90g/l were fewer in the 
placebo group (29%) than in the omeprazole group (43%). Previous ulcer 
history was more common in the placebo group, (56%) versus (45%). 
In Study III, 274 patients were randomized in 34 centers in Denmark, Holland 
and France. Of these, 265 patients could be included in the intention-to-treat 
analysis. Patients were excluded from this analysis if th ey were not given any 
study medication at all (n = 4) , given unknown study medication (n = 2) , 
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violated inclusion criteria (n = 2), or withdrew the informed consent (n = 1). 
Imbalances in baseline factors were found for the following factors; age (38 
patients were above 80 years old in the placebo group compared with 24 in 
the omeprazole group), systolic blood pressure < than 80 mm Hg (placebo 
group - 11, omeprazole group 21), heart failure (placebo group - 23, 
omeprazole group -13), smoking (omeprazole group - 69, placebo group - 51), 
previous ulcer (placebo group - 62, omeprazole group - 47), and Forrest class 
IIa (placebo group - 37, omeprazole group - 20). 
Results (primary efficacy variables) 
The composite ranking scale variable was a primary variable in both Study II 
and III. In both studies we found that patients treated with omeprazole 
showed a statistically significant improved outcome (p = 0.017 and p = 0.004, 
respectively). 
This composite variable has several advantages over the alternative approach, 
that is, to select one individual variable (for instance rebleeding or surgery) as 
the primary efficacy variable. When treating conditions where several 
different treatment options are possible there is always a risk of counteracting 
effects between variables giving in results which are difficult to interpret. The 
composite variable that we used in the present studies circumvents that 
problem by always ranking the patient according to worst outcome. This 
variable also reflects the effect of a treatment in a way that is not necessarily 
picked up by one individual variable, namely a transition of patients from 
more "severe" outcomes to "milder" forms. An obvious disadvantage is that 
the numerical value, the "ranksum" from each treament group, represents 
something "non-tangible" and thus requires more understanding from the 
reader than for instance a discrete variable such as number of operations. 
In Study II, the number of t ransfused blood units was an additional primary 
variable. We found no significant difference between the number of 
transfused units of blood, with 1.4 units transfused in the omeprazole group 
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and 1.6 in the placebo group. The transfusion policy was strict in the study 
and only 166 of the 322 patients received transfusions. Walt (159) reported a 
considerably higher amount of bloo d transfusions in his study on famotidine 
in patients with PUB (a mean of 3 and 4 units in the famotidine and placebo 
groups, respectively). Higher figures than ours were also reported from 
Branicki (20) where a median consumption of 4 units were noted among 
surviving PUB patients and 10 units among PUB p atients who died. In that 
particular study 58% of the patients had hemoglobin values below 100 g/1 
and 20 % had a systolic blood pressure below 100 mm Hg on admission. In 
Study II corresponding figures were 50% and 12% and in Study III 66% and 
42%, respectively. The blood transfusion rate in Study III was also rather low, 
comprising 2.1 units in the group treated with omperazole and 2.9 units in the 
placebo group. 
In Study II only 5 patients in the omeprazole group and 12 patients in the 
placebo group received more than 5 units of blood. Corresponding figures for 
Study III were 12 and 20 patients, respectively. 
The relative lack of d ifference between the study groups with respect to the 
amount of blood units transfused may be due to the use of effective 
endoscopic or surgical intervention in all patients already at a time when 
rather few blood units had been transfused. This illustrates the susceptibility 
of the variable "blood transfusions" to counteraction with intervention 
variables. 
Results (secondary efficacy variables) 
The need for surgery was a secondary variable in both studies and we found a 
consistent and significant reduction when omeprazole was infused. In Study 
II, 2.5% of p atients in the omeprazole group had surgery compared to 9.8% of 
placebo group patients. The corresponding figures in Study III was 5.4% and 
11.1%, respectively. 
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The logistic regression analysis showed a 87% (95% CI; 97% to 49%, p = 
0.003) reduction of th e need for surgery for patients treated with omeprazole 
in Study II and a corresponding 84% (95% CI; 95% to 47%, p = 0.003) 
reduction in Study III. 
The rate of surgical intervention was in both studies, somewhat lower than 
previously reported in other studies conducted before the era of en doscopic 
treatment (120, 159) but correspond well with the 10% reported in a recent 
Dutch survey (171). 
The need for endoscopic treatment was reduced from 6.7% in the placebo 
group to 3.1% in the omeprazole group in Study II and from 11.1% to 4.6% in 
Study III. The logistic regression indicated, for the patients treated with 
omperazole, a 60% (95% CI; 87% to + 28%, p = 0.12) reduction of the need for 
endoscopic treatment in Study II and a 69% (95% CI; 89% to 14%, p = 0.03) 
reduction in Study III. 
No patient in Study II had both surgery and endoscopic treatment during day 
1-3. One of the operated patients died during day 1-3. 
In Study III five of t he 15 patients who had surgery in the placebo group had 
also undergone a previous attempt to endoscopic hemostasis due to 
rebleeding. This was also the case for three (one died) of the seven patients 
requiring surgery in the omeprazole group. 
Duration of bleeding (that is the number of 12 hour periods with bleeding) 
was significantly reduced (p < 0.02) by omeprazole in both studies. In Study II 
the reduction was from 1.0 (12 hour periods) in the placebo group to 0.6 in the 
omeprazole group, corresponding figures for Study III were 1.3 to 0.9. 
The number of patients with further bleeding with the maximum intensity 
according to the 3 or 4 graded scale used in the respective study, was in the 
placebo groups, 26 and 19 (Study II and III, re spectively) compared with 12 
and 8 in the omeprazole groups. A Wilcoxon test including all classes of 
bleeding intensity showed significant differences with the advantage of 
omeprazole treatment in both studies (0.004 and p= 0.03, respectively). 
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The results from the subgroup analyses of patients who had an ongoing 
bleeding at admission (Forrest lb) are of pa rticular interest since they reflect 
the capacity of o meprazole has to stanch an ongoing bleeding in addition to 
maintaininghemostasis. In this sub-group, 82 patients were randomized to 
either omeprazole infusion (n = 41) or placebo infusion (n = 41). The ranking 
scale variable showed a significantly improved outcome for patients treated 
with omeprazole, (p=0.01). Other variables showed numerical, but not 
statistically significant, differences again favoring omeprazole treatment 
(need for surgery, 1 in the omeprazole group, 7 in placebo group, need for 
endoscopic treatment, 0 versus 2, mean number of blood transfusions 1.4 
versus 2.1). 
To summarize, all efficacy variables consistently revealed better results for 
patients treated with omeprazole infusion regardless of w hether the patients 
had an ongoing or a stanched bleeding when treatment commenced. 
These findings are in agreement with some previously presented results after 
repeated omeprazole bolus injections (22) but contrast the relative lack of 
effect reported in the largest single study including patients with all forms of 
upper gastrointestinal bleeding (39). Several explanations to this discrepancy 
exist, for instance, the different patient groups. Presumably patients with 
peptic ulcer bleeding benefit more from omeprazole therapy than patients 
with any other bleeding sources. Another major reason behind the differences 
in effects was the difference in level and duration of acid inhibition achieved 
by the omeprazole dosing regimens used. In the study by Daneshmend (39) 
omeprazole was given as 4 injections of 80 mg, 40 mg, 40 mg and 40 mg, 
respectively over a period of 20 to 27 hours which was followed by oral 
treatment 40 mg twice daily for three days. This regimen will not give a stable 
intragastric pH at the same levels as 80 mg + 8 mg/h during the risk period 
for rebleeding, i.e., the first three days of adm ission and thus does not fulfill 
the theoretical  requests for an adequate hemostatic effect  (88 ) .  
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Follow-up analyses 
The primary objectives of Study II and III were to evaluate the effects of 
omeprazole in PUB patients during a three day infusion. However, as a safety 
measure a follow-up analysis of final outcome and further interventions was 
included day 21 in both study protocols, Table 6. As all patient groups 
received omeprazole 20 mg daily after day 3, we did not expect any 
differences between groups during this period (i.e., day 4 to day 21). 
Table 6. Results of the follow up analyses. Figures refer to day 4 to day 21. 
Omeprazole and placebo refers to allocated treatment day 1-3. 
Study II Study III 
Event Omeprazole Placebo Omeprazole Placebo 
Endoscopic or surgical treatm. 9 3 8 6 
Rebleeding 5 4 9 16 
Therefore it seems as if the advantages shown by omeprazole treatment 
during the first three days are not counteracted by increased rebleeding rates 
during the subsequent days. 
Mortality 
Although a reduction of mortality is the ultimate goal for all therapies in 
patients with PUB it has to be realized that to be able to show statistically 
significant reductions, very large studies will be needed. Langman (101) drew 
parallels with the situation for cardiologists who, in their attempts to find 
significant reduction in mortality had to include more than 10 000 patients in 
survival studies. For instance, to detect a 20% mortality reduction in an 
actively treated group of patients would require, if true mortality in the 
control group is 5%, more than 13 000 patients (a = 5%, 80% power). 
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Mortality was still included in both studies as an efficacy variable at day 3 
and also as a safety variable at the follow-up on day 21 but no significant 
differences were expected to be found based on the considerations outlined 
above. 
At the third of four planned analyses of mortality by the independent 
reviewer the study Steering Committees were informed that there was a 
mortality imbalance in both studies with lower mortality figures in the 
placebo groups. 
An external expert group reviewed the data and recommended the Steering 
Committees to discontinue further inclusion of patients while a thorough 
investigation was performed. 
The final analysis of mortality revealed that after the three days of i nfusion 
one patient in each group (0.6%) in Study II had died and two patients (1.5%) 
in the omeprazole group in Study III. The cumulated number of deaths at day 
21 were, in Study II, one (0.6%) in the group initially treated with placebo 
infusion and 11 (6.9%) in the group initially treated with omeprazole. In Study 
III eight patients in each group had died, i.e., for the placebo group a 
mortality of 5.9%, and 6.2% for the omeprazole group. Figure 5, a and b, 
shows cumulative number of dea ths during days 1 to 21. 
The Steering Committees decided later not to resume inclusion and instead 
perform the efficacy analyses since the included number of patients was 
sufficient enough to detect true treatment effects very close to those which the 
studies originally had been planned for. 
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Figure 5 a and b. Cumulated number of deaths in the two treatment groups a) Study 
II and b) Study III, respectively. 
The mortality figures in both active treatment arms are relatively low in 
comparison to figures reported from similar patient groups , Table 1. The 
mortality figure in the placebo group in Study II is extraordinarily low in 
comparison to in the literature as well as from Study III. A thorough 
investigation was carried out to find any possible causes to the mortality 
imbalance in Study II. This evaluated both the possibility of a positive effect 
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on mortality of t he placebo formulation, mannitol, as well as the possibility of 
an adverse effect of omeprazole. 
The effect of mannitol has been investigated in a large number of studies, 
mainly using mannitol as a hydroxyl scavenger to reduce the ishemic damage 
after thromboembolic events in the brain or myocardium (54, 60, 117, 125, 156, 
168). The results have, however, been inconclusive and the doses used are at 
least a 1000-fold higher than the doses we used in our trials (which were 
about 2mg/kg/24 hours). 
However, to exclude effects that the low doses of mannitol used in our studies 
could have on the coagulation system, which gave a plasma concentration of 
about 0.5 - 1.0 mg/ml, a few pilot in vitro experiments were made. Human 
plasma with mannitol added in concentrations from 0.1 to 100 mg/ml was 
used. Mannitol showed no effects in these concentrations in standard APTT 
analyses as well as in platelet aggregation screen models which are described 
on page 58. 
Imbalances in risk factor distribution between treatment groups at base line 
might be one factor contributing to the mortality imbalance, see page 48. 
These differences are, however, not likely to explain the whole difference. 
Another variable of in terest in this context is the number of n on-fatal serious 
adverse events. In both Study II and Study III only minor differences between 
the placebo and the omeprazole groups were found. Major imbalances at base 
line as well as any harmful effects of om eprazole per se, should have affected 
the number of non-fatal adverse events seen in the two groups. 
Emerging data from Study IV and VI clearly show that the mortality of 0.6% 
at day 3 with no further deaths occurring up to day 21 found in the placebo 
group which was found in Study II must be regarded as an extraordinary 
finding. The mortality in the omeprazole arms in both studies corresponds, 
however, very well to what was found in Study IV and VI and to figures from 
the literature, Table 1. 
Influence upon mortality by chance is, however, one factor which has to be 
seriously considered and has in fact provided a likely explanation to 
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unexpected findings in other studies (64 ,  152) .  Therefore, influence by chance 
must be recognized as the most reasonable explanation behind the mortality 
imbalance also seen in Study II. 
Effects of omeprazole upon hemostatic mechanisms (unpubl. data) 
The positive effect of o meprazole observed in Study II and III is most likely 
achieved by the effect of omeprazole reducing intragastric acidity. However, a 
direct effect of omeprazole on the hemostatic mechanisms can not be 
excluded from these findings. Therefore we have carried out a series of 
experiments to investigate the possibility of a n effect of omeprazole upon: 1) 
platelet function, 2) coagulation 3) bleeding time and 4 ) fibrinolysis. 
1) Platelet function 
Platelet aggregation was measured in an aggregometer which measures light 
transmission in a platelet suspension under continuous stirring at 37"C. 
The effect is expressed in terms of lag phase (the time between addition of 
aggregating agent and the start of aggregation) and the final aggregation 
level. This is a standard method with a reproducibility of ± 3% (final 
aggregation level) (12). Normal maximum aggregation level is 80 - 100%. 
Normal lag time is less than 60 seconds according to the manufacturer's 
information. 
The platelet aggregation in platelet rich plasma and presence of omeprazole in 
concentrations of 0,1, 3,10, 30,100 |j.mol/l was monitored versus time in four 
parallel experiments both with and without adding the platelet activating 
agents collagen (2 mg/ml) or adenosine diphosphate, ADP (200 n.mol/1). 
Omeprazole, given as a bolus infusion of 80 mg over 30 min followed by a 
continuous infusion of 8 mg/h gives a peak plasma concentration of 
approximately 10 pmol/1 and a steady state concentration of 2 pmol/1 in 
healthy volunteers. 
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Omeprazole had no effect on platelet aggregation as seen from the maximum 
aggregation level, Figure 6, or lag phase, Table 7. 
Max. aggregation, % 
80- 1 
60-
—•— No additives 
"• Collagen 
ADP 
20-
—i 1 1 1 1 1 1 1 1 1 1 1 1 i 1 1 1 i 1 
10 20 30 40 50 60 70 80 90 100 
Omeprazole pmol/L 
Figure 6. Effect of omeprazole o n the maximum platelet aggregation in platelet rich 
plasma (all values within normal range). 
Table. 7. Effect of omeprazole upon lag phase of collagen induced platelet 
aggregation (all values within normal range). 
Omeprazole conc., Lag phase 
Hmol/1 plasma sec  
0 45 
1 45 
3 45 
10 45 
30 50 
100 44 
2) Coagulation 
The effect of various concentrations of omeprazole on activated partial 
thromboplastin time, APTT, was studied using a coagulometer. This is a 
standard method (99) measuring the time to plasma coagulation after adding 
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an APTT reagent and calcium chloride to a plasma sample. The experiment 
was performed with and without adding omeprazole (final concentrations of 
1, 3,10,30, 75,100 |imol/l) to the plasma sample. 
The normal range, given by the manufacturer is 34.5 sec. (SD 2.4 sec. ). 
Omeprazole, was found to have no effect upon APTT, Table 8, in these 
concentrations. 
Table 8. Effect of omeprazole on APTT 
Omeprazole conc., APTT, 
Hmol/1 plasma s  
3) Bleeding time 
Anaesthetized male Sprague-Dawley rats were used and the dorsal aspect of 
the tails were incised in a standard manner (40) whereupon bleeding time was 
measured from the moment of incision until the bleeding stopped. The tail 
incisions were made 10 min. before, 20 and 30 min. after the drug was 
administered. The study included 10 animals in each of two groups. One 
group was given vehicle only and the other group was given omeprazole in 
the vehicle. Omeprazole was given as a bolus i.v. infusion over 6 min. and in a 
dose of 100 n.mol kg Plasma concentrations of omeprazole were measured 
at the end of the experiment. 
The bleeding times was not influenced by omeprazole, Table 9. Plasma 
concentration of omeprazole 40 min. after start of i.v. infusion was 13.1 (2.1) 
0 
1 
3 
10 
30 
75 
100 
35.3 
34.8 
34.6 
34.2 
34.3 
34.9 
34.9 
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(imol/l, (mean (SD), which approximates the maximum plasma levels 
obtained after infusion of 80 mg over 30 min (approximately 10 ^ imol/1). 
Table 9. Bleeding time, (min.), in the two groups of rats (n=2 xlO). 
Values are mean (SD). 
Group 1 Group 2 
(Vehicle) (Ome+ veh.) 
Incision 1 2.75(0.49) 2.83(0.67) 
(10 min. before drug) 
Incision 2 2.50(0.46) 2.75(0.42) 
(20 min. after infusion start) 
Incision 3 2.93(0.50) 2.87(0.81) 
(30 min, after infusion start)  
4 ) Fibrinolysis 
In this experiment a modified euglobulin clot lysis test was used (169) .  
Euglobulin was precipitated from human plasma, dissolved and mixed with a 
plasminogen activator (t-PA). Omeprazole was mixed with reptilase and 
added to the euglobulin/ (t-PA) mixture in a light absorbance microplate 
reader. Rapid coagulation took place and the subsequent lysis time (enhanced 
by adding t-PA) of the euglobulin clot was measured. The final omeprazole 
concentrations analyzed were 1,3, 30,100)a.mol/l. 
Omeprazole did not influence clot lysis time at these concentrations, Table 10. 
Table 10. Euglobulin lysis time at different omeprazole concentrations. (All values 
within normal range). 
Omeprazole conc., Euglobulin lysis time, 
limol/1 min. 
0 
1 
3 
30 
100 
104 
108 
110 
109 
107 
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Summary of the effect upon hemostasis 
The four pilot studies 1) to 4) above did not show that omeprazole had any 
effect on platelet aggregation, coagulation, bleeding time or fibrinolysis even 
at plasma levels up to 10 times maximum levels reached after therapeutic 
infusion of omeprazole. A reasonable assumption is therefore that the 
beneficial effects that omeprazole is seen to have in patients with peptic ulcer 
bleeding occur as a result of omeprazole's effect upon intragastric pH. 
Risk factor analyses (Study IV, V, VI) 
Rebleeding 
From the risk analysis in study V we found that age above 60 years, shock at 
admission and smoking significantly increased the rebleeding risk. Age 
showed an OR of 1.03 (95% CI; 1.00 -1.07) per year over 60 years, shock an OR 
of 4.52 (2.23 - 10.04) and smoking an OR of 1.74 (0.98 - 3.08). The prognostic 
importance of these factors is well recognized (78) and further substantiates 
the results from these trials. 
We also found that gastric ulcers were associated with a significantly lower 
risk of rebleeding with an OR = 0.59 (0.36 - 0.98). The importance that ulcer 
localization has on rebleeding risk is an area of debate and results in the 
l i terature are inconsistent  (21 ,78 ,84 ) .  
Intake of NSAID/ASA significantly lowered the risk of r ebleeding, OR = 0.53 
(0.28 - 0.95). This finding can be difficult to comprehend but platelets have 
been reported to play a minor role in the hemostatic process in the gastric 
mucosa (265) which could explain why, at least, no negative effect upon 
rebleeding was seen. Again the literature is inconsistent, a recent Dutch report 
(170), showed an increased rebleeding rate for NSAID/ASA users (16.7% 
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versus 42.9%, p = 0.05) while others, (29) have found no difference with 
respect to rebleeding, 19% for non-users versus 20 % for users. 
Short term mortality 
In all studies (IV, V, VI) mortality was registered up to 30 days in all patients. 
Many deaths occurred outside the hospital shortly after discharge which 
emphasizes the importance of extending the length of follow-up beyond 
discharge date as well when data from patients admitted with a PUB are 
presented. Since most other studies have not specified the length of follow-up 
or just followed patients until discharge direct comparisons are difficult. 
There was an almost linear increase in cumulated number of d eaths over the 
first 30 days in both Study IV and study VI as can be seen in Figures 7 and 8. 
Both studies also clearly illustrate the high proportion of deaths during the 
second half of th e first 30 days after admission. 
No. of deaths 
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Days after admission 
Figure 7. Cumulated number of deaths in Study IV (n=676). 
64 Results & Comments 
45 
40 
35 
30 
25 
20 
15 
10 
5 
0 0 15 20 25 30 
Days after admission 
Figure 8. Cumulated number of deaths in Study VI (n=1020). 
Age 
In all three studies (IV, V and VI) patients over 60 years were found to have a 
significant increase in mortality compared to a 60 year old patient. Study IV 
and V showed, a 4.2 and 2.8-fold increased risk of dying, respectively, for a 75 
year old patient and a 10.8 and 5.4-fold increased risk for an 85 year old. 
These figures compares very well with the 4.2-fold increased risk in the age 
interval 70 - 79 years and 6.2-fold increase between 80 and 89 years of age in 
Study VI. Our results thereby support the negative influence of age which has 
consistently been reported in previous studies (20,128,159). 
Sex 
In Study IV and V, including patients over 60 years, the variable female sex, 
indicated a lower mortality risk with an OR of 0.7 (0.3 - 2.0) and 0.6 (0.2 -1.5), 
respectively, thus indicating a non-significant risk reduction of 30 - 40%. In 
study VI, including patients over 30 years of age the contrary was found with 
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a 2 - fold increased risk for women. One explanation to this apparent 
discrepancy may be related to the different age cohorts included and the 
prognostic impact of female sex may thus be different in young compared to 
old patients. 
Walt (159) included sex in his multivariate analysis of risk factors for death but 
did not list it among factors reported as having significant impact. The 
influence of sex upon outcome has also been analyzed in other studies, but 
not with a multivariate approach. These results must therefore be evaluated 
with caution since the outcome is easily influenced by confounding. 
Ulcer site 
No consistent pattern was seen regarding the prognostic importance of the 
ulcer site in studies IV, V and VI. Two of them indicated a 24% - 55% lower, 
but not significant, risk for gastric ulcers. Study IV showed a 25% higher risk 
in gastric ulcers, however, with a very wide 95% confidence interval why no 
firm conclusions can be drawn. 
The age factor will distort the results if n o proper allowance is made in the 
analysis since patients with gastric ulcers have a higher mean age than 
duodenal ulcers patients (18, 19). Walt corrected for age and found a 
numerical, but insignificant increased risk, 32%, for gastric ulcers. 
NSAIDs 
In Study IV and V, the variable NSAID intake also included ASA intake. Both 
ASA and non-ASA NSAIDs inhibit prostaglandin-dependent protective 
processes in the gastric mucosa and may cause ulceration via topical injurious 
and/or systematic effects (100,158). Both groups of d rugs also inhibit platelet 
aggregation, either irreversibly (ASA) or reversibly (non-ASA NSAIDs). It can 
thus be assumed that the prognostic influence should be similar for both 
substance groups at least if mediated through these mechanisms. 
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In Study V the OR for NSAID intake was 0.45 (0.16 - 1.26) thus indicating a 
risk reduction of 55% for mortality. It can be assumed that the data in this 
study reflect the true situation, since it is based upon a prospective collection 
of data, which was later verified by local study monitors after control of 
hospital records. In Study IV and VI, reporting a insignificant risk increase, 
(OR =1.2 and RR = 2.0, respectively), the accuracy of these data may be 
comparatively lower. Since the 95% confidence intervals all, to some extent 
overlap no firm conclusions can be drawn. One possibility is that the latter 
studies more likely reflect a regular intake of h igher doses while, in Study V, 
also lower and more irregular intake is reported. The possibility of dif ferences 
in the risk impact of low doses and high doses should also be considered. 
These speculations need of course to be investigated in future studies but may 
offer a possible explanation to the confusing and contradicting findings in the 
literature. Jensen and co-workers (SO) were unable to show any significant 
influence of NSAID/ASA intake on rebleeding and mortality in patients with 
PUB. Both variables showed, however, lower values among those taking 
NSAID/ASA. Others (29) have also reported numerically lower mortality 
among NSAID users, (2.6% versus 5.3%). Silverstein (143), in the ASGE, 
survey found a lower mortality both among ASA (13.6% versus 4.9%, p 
<0.001) and NSAID users (6.2% versus 11.0%, n.s.) than in non-users. 
In another study (4) a significantly higher mortality was reported a among 
NSAID users but it was also pointed out that these patients were older and 
had more concomitant diseases. A recent study (170), showed a numerically 
higher mortality (9.5% versus 4.2%,) among NSAID users but no correction 
for influence of age was done. 
Blair (24) like others (66) have described that patients admitted with a PUB 
have a hypercoagulable state during the days subsequent to the bleeding and 
that thromboembolic complications are relatively common after ulcer 
bleedings (14). NSAIDs impair the platelet aggregation, and this may be the 
reason why NSAID intake may be of benefit in this particular respect. 
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The question whether NSAID intake may actually decrease short-term 
mortality after a PUB is not yet answered. Such an hypothesis can, however, 
be formulated to challenge investigators to carry out formal studies. Data 
from Walan and co-workers (257) and the recently emerging data from 
Hawkey and co-workers (62) ensures thè safety of NSAID intake during 
concomitant omeprazole therapy for ulcer healing, which opens up the 
possibility for a well designed study. 
Shock/Low systolic blood pressure 
The prognostic value of hem orrhagic shock on admission was investigated in 
Study IV and V. In Study V the OR equaled 2.21 (95% CI; 0.71 to 6.82) 
indicating a pronounced effect compared with the OR of 1.1 (0.4 to 3.7) in 
Study IV. Again the accuracy of the data in Study V is higher and more likely 
to represent the true situation. 
A systolic blood pressure below 100 mm Hg on admission indicates, as well as 
shock, a substantial blood loss and it is therefore likely to have the same 
impact on mortality as shock. This was also found to be true in Study V with a 
OR of 1.06 (1.01 - 1.11) for each mm below 100 mm Hg. This implies that if a 
patient has a systolic blood pressure of 80 mm Hg on admission the risk 
increases with a factor of 3.21 (1.062" = 3.21) 
Previous ulcer history 
In Study IV, 38% patients reported a previous peptic ulcer (bleeding or non-
bleeding), in Study V 47% (bleeding or non-bleeding) and in Study VI, 38% 
(23% non-bleeding and 15% bleeding). Corresponding figures from other 
studies are 17% and 19% in one study (44) and 22% and 10% in another (235). 
In Study V and VI significant risk reductions were found for patients with an 
ulcer history with an OR of 0.26 (0.09 to 0.74) and a RR of 0.33 (0.14 to 0.83), 
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respectively. The retrospective Study IV, however, indicated no prognostic 
influence (OR of 1.0 (0.4 to 2.5)). 
A few previous studies have reported lower mortality rates in patients with 
previous ulcer history but these findings have not attracted much interest (43, 
81,139). Branicki and co-workers (20) presented in a study of 701 patients with 
PUB a mortality of 1.8% among patients with previous ulcer history and a 
mortality of 6.9% (p < 0.01) among those without. Wara (161) reported that a 
history of dyspepsia was also associated with a better overall outcome after 
PUB. 
There may be different explanations why PUB patients with previous ulcer 
history seem to have a lower case-fatality rate. Most patients with an ulcer 
history have an H. pylori infection and/or NSAID intake as the pathogenic 
factor. In contrast, in elderly patients admitted due to their first PUB, other 
pathogenic mechanisms may also be involved, for instance, impaired 
defense/repair mechanisms. Such impaired defense mechanisms may be a 
result of a severe general decline in health status and thus it may actually be 
the underlying condition and health deterioration that causes the ulcer and 
ultimately leads to death. This theory was also recently been presented by 
Hudson and co-workers (74). The bleeding ulcer in these patients could thus 
be looked upon more as an epi-phenomenon than a separate disease. A 
decline in health status may, for instance, be due to a silent myocardial 
infarction or an, as yet, undetected malignancy. 
Based upon autopsy findings, ulcers seem to be a common and often 
undetected phenomena in terminal disease (104,106) which support the theory 
that ulcers commonly develop during the terminal phase of a patients life. 
Other explanations to the results must of course also be considered. These are, 
for instance, differences in preventive drug treatment, different treatment 
policies for an index and a recurrent bleeding, or a higher health awareness 
among patients with ulcer history. 
A selection phenomenon may also play a role. Previous bleeding episodes, 
during which the most fragile patients die and thereby selecting the healthier 
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ones to be exposed to the risk of a second bleeding,could have this effect. 
However, the risk reduction was also found in patients with ulcer history 
without bleeding (and thus no selection phenomenon) who had a RR of 0.38 
compared with a RR of 0.27 for those with previous bleeding (VI). This 
finding rejects the suggestion that a selection phenomenon could be the 
reason for the lower mortality among patients with ulcer history. 
However, additional studies are required to further substantiate the findings 
and possible underlying mechanisms. 
Risk factors for long term mortality 
The long-term survival curves for men and women in Study IV showed a 
very similar pattern. 
Compared with their matched controls, women had a significantly higher risk 
of d ying after the first 30 days of ad mission. Men showed a small and non­
significant increase compared with their controls, Figure 9, a and b. 
None of the analyzed factors in Study IV w ith the exception of ag e showed 
any significant association with long term survival despite the finding that 
women had a s ignificantly increased mortality, adifference of a pproximately 
15% after 5 years, compared with their controls. Whether this finding also 
applies to women with non bleeding ulcers is not clear. 
The magnitude of this mortality difference, however, requires further 
research in order to find the cause of this increased long term mortality. 
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Figure 9, a and b. Surviving proportions (95% CI) among men and women 
in Study IV compared with their matched controls 
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A review of the causes of d eath in Study IV revealed that exsanguination or 
death due to other ulcer complications occurred only by way of exception and 
can not explain the increased mortality among PUB patients. The most 
common causes of death were, as expected in an elderly cohort, mainly 
cardiovascular events. The recently alleged association between H. pylori 
infection and cardiovascular morbidity/mortality is still an area with 
conflicting results (112, 121, 148) and it will be of great importance to study 
whether eradication of H. pylori not only prevents rebleedings (79) but may 
also have an impact on mortality in the long-term perspective. 
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SUMMARY AND CLINICAL CONSIDERATIONS 
Peptic ulcer bleedings cause approximately 2500 - 3000 hospital admissions 
per year in Sweden and the proportion of these patients who are over 60 years 
is steadily increasing. The primary objective for the initial treatment at the 
hospital is to achieve rapid hemostasis in order to avoid exsanguination and 
ultimately death. Endoscopic intervention therapy has gained an increasing 
popularity and is, in the hands of a skilled endoscopist, highly effective in 
stopping the index bleeding and secondly it reduces the risk of rebleeding by 
30-40%. Still, we have to realize that approximately 20 % of the patients will 
experience a rebleeding necessitating repeated endoscopic treatment or 
surgery. 
The majority of the admitted patients will not, however, be treated primarily 
at a hospital with the resources and competence to offer endoscopic 
hemostatic therapy 24 hours a day 365 days a year. This situation is not likely 
to change during the coming years. Based on these considerations, there is an 
apparent need for an effective treatment that can be given to all PUB patients 
without the need for special equipment or resources. This would allow the 
patients to stabilize before the subsequent endoscopic treatment or be offered 
as an effective therapy allowing definitive hemostasis in those instances 
where a trained endoscopist is not immediately available. 
The present study has evaluated the effect of a primed infusion of 
omeprazole, 80 mg/h + 8 mg/h in high risk patients both after and without 
endoscopic treatment and we have found that this treatment regimen, 
significantly improved outcome, reduced the need for surgery by 84% - 87%, 
and the need for further endoscopic treatment by 60 - 69%. 
We can also conclude that infusion of om eprazole administered according to 
the current regimen exerts an additional effect to that of endoscopic treatment 
and it also seems to have the capacity to induce hemostasis in ulcers with an 
ongoing oozing bleeding. 
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The current results clearly indicate the potential of omeprazole infusion 80 mg 
+ 8 mg/h in the immediate clinical management of patients admitted due to a 
PUB. It is interesting to note that a similar treatment algorithm has been 
presented for bleeding complications in patients with portal hypertension 
(224). In this situation resuscitation of the patient and nasogastric intubation 
coincides with the start of d rug therapy to arrest the bleeding, which allows 
time to prepare for definitive endoscopic therapy. 
In the clinical studies we consistently infused a dose of 80 mg + 8 mg/h. It 
can be argued that the continuous infusion dose of omeprazole could be 
decreased and the results from the dose-finding study (I) c ould not exclude 
this possibility. We can, however, claim that the very strict criteria, to have a 
stable intragastric pH over 5.4, was essentially fulfilled with the current dose. 
The present study also added important data on the overall mortality pattern 
after a PUB. The risk of a fatal outcome remains high even though a durable 
hemostasis has been achieved and furthermore, the risk seem to be elevated 
during the entire first month after the bleeding event and not only confined to 
the hospitalization period. The cause of death was in most cases 
cardiovascular or cerebrovascular events. 
In Sweden, we can estimate that the annual death rate due to a PUB is 200 -
300. In our analysis of risk factors for mortality we have found that the risk 
was considerably higher in patients being over 60 years of age or in shock on 
admission. In addition, patients who experienced their first ulcer event had a 
higher risk. 
Traditionally, clinical research in this field has focused on reducing the rate of 
rebleeding with the belief that this would ultimately reduce mortality as well. 
However, despite significant reductions in variables related to rebleeding we 
have not been able to show any corresponding reductions in mortality. Thus, 
it may be time to challenge the assumed causal relationship that an effective 
prevention of rebleedings leads, by necessity, to a reduction in mortality. 
Future research in this field must seriously consider other possibilities of 
reducing mortality. The finding, in one of the studies, of a lower day 30 
74 Summary 
mortality in NSAID users raises, together with the fact that patients with a 
PUB have a hypercoagulable blood status and that thromboembolic events are 
the most common reason for death, a new and intriguing question. Does 
thromboembolic prevention measures, for instance with low dose ASA, 
prevent late cardiovascular complications after a PUB which may eventually 
lead to death? As early as in 1989, Walan and co-workers (357) demonstrated 
that omeprazole was equally effective in healing gastric ulcers regardless of 
concomitant ASA/NSAID intake. Recently data emerging from Hawkey and 
co-workers (62) have shown that omeprazole treatment leads to high healing 
rates of NSAID induced lesions, even if the NSAID treatment is continued. 
This indicate a safe basis for a potential study design evaluating, for instance, 
low dose ASA (in combination with omeprazole) as a preventive measure of 
cardiovascular events during the first month after a PUB. 
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